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Summary 
Myb-binding protein 1A (MYBBP1A) is a nucleolar protein implicated in stress response and 
carcinogenesis. However, its functional contribution to cellular senescence as well as the clinical 
relevance in head and neck squamous cell carcinoma (HNSCC) have not been addressed so far. 
In the present study, a cell culture model of genotoxic senescence, which was induced by the 
topoisomerase II inhibitor VP-16, was established to unravel the role of MYBBP1A in cellular 
senescence. Interestingly, in response to DNA damage, MYBBP1A first translocate from the 
nucleolus to the nucleoplasm and subsequently, its protein levels decreased in senescent cells. 
Loss-of-function approaches in tumor cell lines provided further evidence that silencing of 
MYBBP1A was not sufficient to trigger senescence, but that it modulated the efficacy of 
genotoxic-induced senescence and augments resistance to irradiation. Although, the precise 
molecular mechanism by which MYBBP1A regulates DNA damage-induced senescence remains 
elusive and warrants further investigation, this study revealed an inverse regulation of 
MYBBP1A and AKT(Ser473) phosphorylation to be a characteristic feature of senescent tumor 
cells. Most strikingly, immunohistochemical analysis of tissue microarrays with tumor 
specimens from primary oropharyngeal squamous cell carcinoma (OPSCC) patients (n=61) 
revealed that a MYBBP1A
low
pAKT(Ser473)
high
 staining pattern serves as an independent marker 
for poor clinical outcome. Remarkably a significant correlation with progression-free or overall 
survival was not found considering pAKT(Thr308) levels, suggesting a more critical role of the 
mTOR/AKT pathway for the clinical behavior of OPSCCs with low MYBBP1A levels. In 
summary, these data demonstrate that tumor cells with a MYBBP1A
low
 but pAkt(Ser473)
high
 
protein pattern have a senescent-like phenotype and might critically contribute to tumor 
progression due to the emergence of highly malignant and/or therapy resistant tumor cells. 
Moreover, the abundance of MYBBP1A
low
pAKT(Ser473)
high
 senescent tumor cells in primary 
tumors as well as following tumor relapse could serve as a reliable biomarker for treatment 
decision making and to stratify HNSCC patients at high-risk for treatment failure. Thus, 
restoration of MYBBP1A function or pharmacological inhibition of the PI3K/mTOR/AKT 
pathway is an attractive new concept not only to sensitize tumor cells for available treatment 
options, but also to establish new strategies for targeted therapy with the potential of elimination 
of senescent cells. 
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Zusammenfasung 
Myb-binding protein 1A (MYBBP1A) ist ein Protein im Nuleolus und ist an der zellulären 
Stressantwort und bei der Karzinogenese beteiligt. Jedoch wurde seine Rolle beim Prozess der 
Seneszenz sowie die Relevanz von seneszenten Tumorzellen beim Plattenepithelkarzinom der 
Kopf- und Halsregion (HNSCC) bislang nicht untersucht. In der aktuellen Studie wurde durch 
die Applikation des Topoisomerase II Inhibitors VP16 ein Zellkulturmodell für genotoxische 
Seneszenz etabliert, um die Regulation und Funktion von MYBBP1A bei der zellulären 
Seneszenz aufzuklären. Infolge von DNA-Schädigung wurde zunächst eine Translokation von 
MYBBP1A vom Nukleolus in das Nukleoplasma nachgewiesen und anschließend ein Verlust 
von MYBBP1A in seneszenten Zellen beobachtet. Funktionelle Studien in Tumorzelllinien 
belegten, dass eine Hemmung von MYBBP1A nicht für die Induktion der Seneszenz ausreichend 
ist, jedoch das Ausmaß der genotoxischen Seneszenz moduliert und die Resistenz gegenüber 
Bestrahlung steigert. Obwohl die zugrundeliegenden Mechanismen noch aufgeklärt werden 
müssen, zeigt diese Studie eine inverse Regulation zwischen MYBBP1A und AKT(Ser473) 
Phosphorylierung als charakteristische Eigenschaft von seneszenten Tumorzellen. Die klinische 
Relevanz dieser Ergebnisse konnte mittels immunhistochemischer Analysen von Gewebearrays 
mit Tumorproben von Patienten mit einem Oropharynxkarzinom (OPSCC, n=61) gezeigt 
werden. Ein MYBBP1A
low
pAKT(Ser473)
high
 Färbemuster stellte sich als unabhängiger Marker 
für eine schlechte Prognose heraus. Interessanterweise wurde keine vergleichbare Korrelation für 
pAKT(Thr308) nachgewiesen, was auf eine kritischere Rolle der mTOR/AKT Signalkaskade für 
das klinische Verhalten von OPSCC Patienten mit einer geringen MYBBP1A Proteinexpression 
hindeutet. Zusammenfassend demonstrieren die gezeigten Daten, dass Tumorzellen mit 
MYBBP1A
low
 aber pAKT(Ser473)
high
 Proteinlevel einen Seneszenz-ähnlichen Phänotyp 
aufweisen und aufgrund ihrer malignen und therapieresistenten Eigenschaften maßgeblich zur 
Tumorprogression beitragen könnten. Die Häufigkeit von MYBBP1A
low
pAKT(Ser473)
high
 
Tumorzellen im Primärtumor bzw. im Tumorrezidiv könnte als zuverlässiger Biomarker für die 
Therapieentscheidung oder zur Stratifizierung von Risikopatienten für Therapieversagen 
beitragen. Somit stellt die Widerherstellung der MYBBP1A Funktion oder eine 
pharmakologische Hemmung der PI3K/mTOR/AKT Signalkaskade ein attraktives Konzept dar, 
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um Tumorzellen für etablierte Therapieoptionen zu sensitivieren. Alternativ könnten sie die 
Grundlage für neue Strategien der zielgerichteten Therapie bilden mit dem Ziel seneszente 
Zellen zu eliminieren. 
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1 Introduction 
1.1 Head and neck squamous cell carcinoma 
Head and neck cancer encompasses a heterogeneous group of epithelial malignancies arising 
within the upper aerodigestive tract, and presents the sixth common cancer in the world by 
incidence (1, 2). Over 90% of head and neck cancers are of squamous cell histology (HNSCC), 
which originates from the mucosal surfaces of the oral cavity, pharynx, larynx or nasal cavity 
(Fig. 1.1).  
                                  
Figure 1.1: Anatomic sites and subunits of head and neck. HNSCC includes following subsites: oral 
cavity, pharynx, larynx, paranasal sinuses, nasal cavity and salivary glands. Image source: 
www.cancer.gov/PublishedContent/ Images/ cancertopics/factsheet/ Sites-Types/headandneck-
diagram.jpg. 
 
Worldwide, an estimated 644.000 new cases are diagnosed each year and a high incidence is 
seen in the Indian subcontinent, Australia, France and Brazil (Fig. 1.2) (3, 4). Mortality expected 
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to rise in South East Asia by 2030, whereas in Europe is expected to remain stable (5). 
Moreover, studies in both low- and high-income countries have revealed that the patients with 
low socio-economic class and low educational attainment had a greater risk for the development 
of HNSCC, particularly oral cancer (6). The incidence of HNSCC is three-fold higher in men 
than women and reported to increases with age (3, 4). According to the large scale 
epidemiological studies, in Europe 98% of patients diagnosed are over 40 and 50% are over 60 
years of age (3).  
                      
Figure 1.2: Worldwide mortality and incidence figures of head and neck cancer. Estimated figures in 
2008 for head and neck cancers. Population number should be multiplied by 1000. (Data taken from 
Mehanna et al. 2010 (3)). 
 
The major risk factors so far identified are tobacco (smoking and smoke-less products such as 
betal quid) and alcohol consumption, account for about 75% cases with HNSCC. The combined 
effect of tobacco and alcohol causes a synergistic increase in risk (7). In the western world, 
public health measures have been successful in reducing the use of tobacco, and therefore 
attributed to a decrease in the incidence of HNSCC during the past decade. However, there has 
been a dramatic increase in the incidence rates of oropharyngeal squamous cell carcinoma 
(OPSCC), which may be related to an increase in oral and oropharyngeal human papilloma 
viruses (HPVs) infections especially with HPV subtype 16 (HPV-16) (8, 9). Importantly, the 
HPV status was found to have a profound influence on patient survival. Patients with HPV-
positive HNSCC showed improved survival outcomes compared to those with HPV-negative 
HNSCC irrespective of treatment modality (10). Although Epstein-Bar virus infection (for 
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nasopharyngeal cancer) and inherited disorders such as Fanconi anemia render a predisposition 
for the disease, they play only a minor role (11, 12). A diet rich in fruits and vegetables has also 
been shown to have the most promising effect to reduce the risk of HNSCC (13).  
1.1.1  Molecular pathology of HNSCC 
HNSCC is a heterogeneous disease, which involves a multistep process starting from normal 
epithelium progressing through hyperplasia to dysplasia to carcinoma in situ and invasive 
carcinoma (Fig. 1.3). A plethora of studies has been published on the identification of cancer-
related genes and frequently found genetic changes in HNSCC, most importantly on 
chromosomal arms 3p, 17p and 9p (14-16). Thus progressive accumulation of these alterations in 
oncogenes, proto-oncogenes and tumor suppressors can lead to the formation of a malignancy  
often precedes to acquire a characteristic phenotype that includes, limitless replicative potential, 
changes in growth factor signaling, ability to evade apoptosis, invasion, metastasis and 
angiogenesis (17, 18).    
                
Figure 1.3: Genetic progression model for HNSCC. Head and neck cancer is progressed through a 
multistep processes from normal mucosa through the advancing stages of squamous dysplasia to invasive 
carcinoma and is driven by the progressive accumulation of genetic alterations. Genes and pathways 
involved are depicted. Modified from Pai et al. 2009 (15). 
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Cellular proliferation: p53/Rb/CDKN2A/CCND1 
The TP53 and retinoblastoma (Rb) pathways are disrupted in almost all HNSCC patients, result 
in limitless replicative potential and immortalization. Mutations in the TP53 tumor suppressor 
gene are one of the earliest identified genetic alterations in HNSCC, reported in 60-80% of cases 
(19). In HNSCC, an increased TP53 mutation rate is associated with tobacco and alcohol use, 
further contributes to the clinical behavior of tumors (20, 21). Most notably, in p53 wild-type 
tumors the abrogation of p53 function may be mediated by other mechanisms. These include 
expression of the HPV viral oncoprotein E6, overexpression/amplification of MDM2 and 
deletion of CDKN2A, which eliminates the p14/ARF gene (22-25).  
pRb is targeted early in the carcinogenesis of HNSCC by the inactivation of CDKN2A, encoding 
the cell cycle regulators p16/INK4A and p14/Arf/INK4B. CDKN2A mutations were found in 
approximately 7-9% of tumors, with copy number losses in further 20-30% cases (26, 27). In 
HPV-positive HNSCC, the Rb pathway is inactivated by the viral E7 protein, which binds to 
RB1 and abrogates the requirement for p16/INK4A silencing (28). Furthermore, amplification of 
CCND1 gene, which encodes cyclin D1 on chromosomes 11q13 occurs in over 80% HNSCC, 
more frequently in HPV-negative tumors (29). Thus, abrogation of p53, CDKN2A and 
overexpression of cyclin D1 are associated with decreased survival and used as an independent 
predictors of poor prognosis to genotoxic therapy (30).  
Terminal differentiation: Notch/p63 axis 
One of the novel findings emerged from whole-exome sequencing studies of HNSCC was the 
discovery of inactivating mutations of NOTCH1 gene in 14-15% of the HNSCC tumors, making 
NOTCH1 the second most common mutation after TP53 (26, 27). NOTCH pathway has been 
linked to multiple biological functions, including regulation of self-renewal capacity, cell cycle 
exit, cell survival and promoting terminal differentiation (31, 32). In haematological 
malignancies, NOTCH1 signaling has been reported to be protumorigenic by activating 
mutations (33), whereas in HNSCC, the majority were nonsense mutations, suggesting a tumor-
suppressor function for this pathway (31). Additionally, Notch activity has been linked to the 
downmodulation of HPV-driven transcription of the E6 and E7 viral genes (34). NOTCH1 has 
also been found to be involved in squamous epithelial differentiation, and this is controlled by 
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p53-related transcription factor p63 (35). Overexpression and/or genomic amplification of the 
TP63 locus have been observed in majority of invasive HNSCC (36).             
Cell survival: EGFR/Ras/PIK3CA/PTEN/CASP8 
EGFR overexpression is detected in many cases of HNSCC and often considered to be among 
the most important therapeutic targets (37). Approximately 10-30% of HNSCC display EGFR 
gene amplification, which has been suggested to correlate with poor prognosis (38). However, 
EGFR mutations are rare in HNSCC, reported in only 1-7% of patients (39). Activation of EGFR 
acts as an upstream signaling to both Ras-MAPK and PI3K-PTEN-AKT pathways (40). Ras 
mutations are less common in HNSCC and often observed in relationship to tobacco history 
among the Indian population but less frequently in the western world (41). One of the nuclear 
targets of EGFR is CCND1 that encodes cyclin D1 protein, which involved in cell cycle 
progression (42). 
Another important commonly activated pathway in HNSCC is PI3K signaling, which is one of 
the major downstream targets of EGFR. Phosphoinositide 3-kinases (PI3Ks) are a family of 
enzymes capable of phosphorylating the 3’-OH position of phosphoinositide lipids (PIs) and 
have important roles in promoting cell growth, differentiation, survival, proliferation and 
migration (Fig. 1.4) (43, 44). PI3Ks are activated by RTKs and catalytic subunit phosphorylates 
phosphatidylinositol 1,4-biphosphate (PIP2) to form phosphatidylinositol 1,4,5-triphosphate 
(PIP3), which further recruits phosphoinositide-dependent protein-kinase 1 (PDK1) and AKT to 
the plasma membrane, where it binds by its pleckstrin-homolgy (PH)-domain (31). At the 
membrane, AKT is phosphorylated at Thr308 by PDK1 (45). Full activation of AKT requires 
additional phosphorylation at Ser473 by the mTOR complex 2 (mTORC2) (46). AKT can also 
be phosphorylated at Ser477 and Thr479 by mTORC2 and DNAPK under growth factor 
stimulation and DNA damage, respectively (47, 48). Activation of PI3K/AKT pathway can occur 
by many other mechanism, including: mutation or amplification of PI3K; amplification of AKT; 
activation of upstream oncogenes like RAS; or mutation of the tumor- suppressor protein PTEN 
(Phosphatase and tensin homology). PTEN, encoding a negative regulator, mediates the 
conversion of PIP3 to PIP2 and subject to frequent loss of heterozygosity in approximately 40% 
of HNSCCs (32). Besides inactivating mutations of PTEN, somatic mutations of PIK3CA, 
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encoding a positive regulator of this pathway have also been described in approximately 10-20% 
of HNSCCs (14). 80-90% of HNSCC lesions present activation of the PI3K-AKT-mTOR axis, 
whereas the MAPK and JAK/STAT pathways were mutated in less than 10% of the cases (49). 
Thus, aberrant activation of the pathway tightly associated with tumorogenesis, poor prognosis 
as well as chemotherapeutic and radio-therapeutic resistance in cancer patients (50, 51). Several 
constituents of the apoptotic signaling cascade like caspase-8 (CASP8) and BCL2, encoding a 
key anti-apoptotic regulator reported to have also an important role in HNSCC (32). 
 
Figure 1.4: PI3K pathway. Overview of PI3K/AKT signaling and downstream effects. Modified from 
Psyrri et al. 2011 (52). 
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Additional genes/ Pathways 
TGF-β receptor deletion (53), overexpression of cyclooxigenase-2 (COX-2) (54), vascular 
endothelial growth factor (VEGF) (55), and matrix metalloproteinases (MMPs) (56), are known 
to promote invasion, metastasis and angiogenesis in HNSCC. Various pro-inflammatory 
cytokines are also deregulated in HNSCC, including Interleukin (IL) 1-α, IL-6, IL-8, IL-10 and 
granulocyte-macrophage colony-stimulating factor (GM-CSF). Cross-talk between transcription 
factors downstream of inflammatory processes like NFκB and STAT3 have been shown to drive 
the unrestricted growth of HNSCC cells (57).   
1.1.2 Treatment and outcome 
At present, treatment options for HNSCC are selected in a multidisciplinary setting including 
stage, grade, patient fitness and location of the tumor. Approximately one third of patients with 
HNSCC come to clinical attention with early-stage disease and is treated with surgery, radiation, 
and /or chemotherapy, with cure rates of 70-90% (58). However, the majority of patients 
presents with advanced cancer and requires aggressive multimodality therapy. In the past two 
decades, the quality of life of patients has increased as a results of the use of more advanced 
surgical, radiotherapy delivery techniques and most notably the application of target drugs (such 
as the EGFR-specific antibody Cetuximab) combined with radiotherapy (14). Disappointingly, 
survival as a whole has not markedly improved because patients still frequently develop distant 
metastases, second primary tumors and most importantly locoregional recurrences, with limited 
options for effective treatment (59, 60). Therefore, finding biomarkers that predict response to 
chemoradiation protocols, so as to optimize personalized treatment is paramount.  
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1.1.3 Mouse model for recurrence  
Locoregional recurrent disease is correlated with poor prognosis and is considered being the sole 
site failure in patients who die from HNSCC (61). Already a half century ago the term field 
cancerization was proposed to explain the high rate of recurrences after treatment in patients with 
HNSCC (62). Comparison of the genetic profiles of carcinomas and their surrounding field often 
indicates the presence of areas consisting of epithelial cells with dysplastic changes (63). 
Importantly, these macroscopically normal appearing fields are often retains in the surgical 
margin when the tumor is excised and acquired additional genetic changes to give rise to a local 
recurrence or second primary tumors. Furthermore, experimental and clinical data strongly 
suggest the presence of  these disseminated tumor islands with high invasive potential for the 
development of an invasive carcinoma (64). Accordingly, the cooperative effect of molecular 
alterations in cancer cells and compensatory micro-environmental changes plays a critical role in 
tumor recurrences. Thus, a preclinical animal model is required to better understand the 
underlying molecular mechanism of the disease and the consecutive design of new treatment 
strategies.  
Behren et al. (65) have already developed an orthotropic floor-of-mouth squamous cell 
carcinoma model in mice to study the local recurrence after surgery (Fig. 1.5). In this animal 
model, primary tumors were generated by trans-cervical injection of eGFP-expressing murine 
SCC-7 cells into the floor-of-mouth of BALB/c-nu mice. Local recurrences were obtained after 
microsurgical removal of primary tumors. Global gene expression analysis was conducted on 
whole genome arrays with samples of this mouse model and revealed 49 differentially expressed 
transcripts between primary and recurrent tumors (66). One candidate gene encoded the 
transcriptional co-regulator Myb-binding protein 1A (MYBBP1A).  
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Figure 1.5: Mouse model for recurrence. The mice were injected with SCC-7 cells to develop primary 
tumors. 60% of the mice developed local recurrence after microsurgical removal of primary tumors. 
Global gene expression profiling of samples from primary and the corresponding recurrent tumors 
revealed a list of differentially expressed genes, represented in the heat map. One of the candidate genes 
encoded MYBBP1A. Modified from Sanhueza et al. 2012 (66). 
    
1.2 Myb-binding protein 1A (MYBBP1A) 
1.2.1 Localization and function of MYBBP1A 
Human MYBBP1A is a 1328 aa long protein and was originally identified as an interacting 
partner of the proto-oncogene c-myb (67). The 160-kDa MYBBP1A is a nuclear protein, which 
is expressed ubiquitously and predominantly localized in the nucleolus by binding to nucleolar 
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RNA (68). MYBBP1A is post-transcriptionally processed under pathological conditions of 
nucleolar disruption, post-mitotic cell cycle arrest and shortage of intracellular energy, which 
induce its translocation from the nucleolus to the nucleoplasm (Fig. 1.6) (69-71). The carboxyl 
terminus of full length MYBBP1A, which contains nuclear and nucleolar localization sequences 
(NLS) are necessary for its subcellular localization. Unlike the full-length protein, its shorter N-
terminal 140 kDa and 67 kDa post-transcriptional cleavage products are mainly localized in the 
nucleoplasm due to the processing of NLS (72).  
Nucleolar large MYBBP1A implies an essential role in ribosome biogenesis (70). In addition, 
MYBBP1A interacts with several transcription factors, such as the PGC-1α, Prep1, c-Jun and 
CRY1 and in most cases function as co-repressor (73-76). However, it can also stimulate the 
transcriptional activity of aryl hydrocarbon receptor (AhR) (77). Recent evidences also 
established a critical function for MYBBP1A as an important regulator of NFκB and p53, 
implicated in cell cycle control, inflammation and carcinogenesis. MYBBP1A interacts directly 
with the RelA/p65 subunit of NFκB and inhibits its transcriptional activity (78). In addition, 
MYBBP1A located in the nucleoplasm specifically recognizes non-acetylated lysine residues of 
p53 to promote p53-p300 association, resulting in p53 acetylation and activation. Activated p53 
binds to the target gene promoters and regulates gene expression, resulting in apoptosis or cell 
cycle arrest (69, 79, 80). In this context MYBBP1A act as a sensor in the nucleolus that connects 
intracellular energy status with the cell cycle machinery. MYBBP1A has also been linked to 
mitosis and DNA damage responses, since it was identified as a novel substrate for Aurora-B 
kinase (81) and cell-cycle checkpoint kinase 1 (CHK1) (82). Recent report also unraveled an 
essential role of MYBBP1A in early embryonic development (75). Thus, MYBBP1A has been 
shown to play an important role in essential biological functions such as cell division, cell 
proliferation, development and apoptosis. However detailed mechanisms underlying these 
activities have not been determined.  
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Figure 1.6: Expression and diverse roles of MYBBP1A. MYBBP1A post-transcriptionally processed 
by stress signal to induce its translocation from nucleolus to the nucleoplasm. MYBBP1A interact with 
several transcription factors to inhibit (shown in red) or stimulate (shown in green) its activity and plays 
an important role in essential biological functions.   
 
1.2.2 Regulation of MYBBP1A in cancer 
Recent studies unraveled a potential tumor suppressive role for MYBBP1A in RAS-mediated 
transformation and breast carcinogenesis. Down-regulation of MYBBP1A not only affects the 
expression of several genes which are involved in cell cycle control, DNA damage and cell 
death, it could also enhance the tumorigenicity of Ras-transformed NIH3T3 cells (75). 
Furthermore, in vitro and in vivo experiments using breast cancer cell lines, which express wild 
type p53, revealed that loss of MYBBP1A expression is associated with carcinogenesis, colony 
formation and anoikis resistance (83). In a preclinical mouse model of oral carcinogenesis and in 
HNSCC patients, MYBBP1A expression was reduced in recurrent as compared to matched 
primary tumors, suggesting that loss of MYBBP1A expression promotes malignant progression 
and treatment failure (66). Gain-of-function and loss-of-function studies in head and neck cancer 
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cell lines further highlighted a dual role for MYBBP1A as a key regulator in the cellular decision 
between cell proliferation and migration. Silencing of MYBBP1A expression by siRNA 
technology, results in a significant decrease in tumor cell proliferation and a strong increase in 
tumor cell migration (66). Thus, tumor cells with reduced MYBBP1A expression may represent 
a sub-population of slow-cycling but mobile cells implicated in tumor recurrence and metastasis.  
1.3 Senescence  
Cellular senescence is a state of permanent cell-cycle arrest, despite continued viability and 
metabolic activity of affected cells. It limits the propagation of damaged and stressed cells in 
response to a variety of detrimental stimuli. More than a decade ago, cellular senescence was 
originally identified by Heyflick and Moorhead to describe a state of irreversible growth arrest of 
human diploid cells after serious of passaging in culture and they speculated that it could be an 
underlying reason for ageing (84). Later, this particular type of senescence (replicative 
senescence) was linked to telomere attrition, a process that is implicated in chromosome 
instability and considered to be one of the first reported molecular triggers of senescence (85). 
Senescence induction also occurs in response to the activation of oncogenes such as RAS (86) 
and RAF (87), referred to as oncogene-induced senescence (OIS). Similarly, loss of tumor 
suppressors such as PTEN (88), NF1 (89) or von Hippel-Lindau (VHL) (90) can trigger 
senescence. In addition, oxidative stress and DNA-damage induced by ionizing radiation, UV 
light, chemotherapeutic drugs and pathological increases ROS have been identified as potential 
initiators of senescence (91-93). This type of senescence referred to as stress-induced premature 
senescence (SIPS) (94).  
1.3.1 Molecular pathways of cell senescence 
Initial growth arrest and multiple-step progression of cellular senescence are induced by a variety 
of stress conditions, which mainly trigger excessive DNA damage (91, 93) (Fig. 1.7). Three 
prevalent features, which define cellular senescence includes irreversible growth arrest and 
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activation of molecular pathways, secretion of SASP, and promiscuous gene expression. The 
initial step of cellular senescence involves the recognition of DNA damage and the activation of 
DNA damage responsive (DDR) pathway (95). Amplification of the DDR signal mediated by the 
activation of DNA damage kinases ATM, ATR, CHK1 and CHK2, which further activate several 
cell cycle proteins, including p53. Phosphorylated p53 protein activates the expression of p21, 
while activation of pRb-p16
INK4A
 occurs through p38-MAPK-mediated mitochondrial 
dysfunction and ROS production. Together, these changes halt cell-cycle progression, allowing 
cells to repair DNA damage. But if the DNA damage exceeds a certain threshold, cells undergo 
apoptosis or senescence (93, 95, 96).  
 
Figure 1.7: Molecular pathways of senescence. Multiple stresses trigger the activation of DDR and 
signaling cascades that converge on the activation of cell cycle inhibitors and the tumor suppressor RB. 
ROS activate p16 and p53 through their downstream effector p38. Oncogenic signaling and loss of tumor 
suppressors activate p16 and p53 with the participation of DDR. PI3K and TGFβ pathways are also 
involved to induce senescence through p21.   
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Thus, a sustained DDR is crucial for robust expression of the SASP and chromatin remodeling. 
Several studies subsequently confirmed the critical roles of p53-p21 and pRb-p16
INK4A 
in the 
induction and maintenance of cellular senescence (95, 97, 98). The relative contribution of these 
pathways varies between cell types and activation of only one of these pathways may be 
sufficient to induce senescence (99, 100). Mutant oncogenes and loss of the PTEN tumor 
suppressor have the potential to activate molecular pathways of cellular senescence independent 
of DNA damage (88, 101). PI3K and TGFβ pathways have also been shown to induce 
senescence through p21 in developmental cues (102, 103).   
1.3.2 Hallmarks of senescence 
Senescent cells differ from other non-dividing cells such as quiescent or terminally differentiated 
cells by several markers and morphological changes, which in combination define the senescent 
state (Fig. 1.8). Senescent cells frequently display a large flattened morphology and induction of 
senescence-associated β-galactosidase (SA-β-gal) activity (104). The SA-β-gal reflects the 
increased lysosomal biogenesis that often occurs in senescent cells (91). Expression of tumor 
suppressors p53, p21 and p16 often serve as biomarkers to represent the arrest of the cell cycle. 
Another obvious marker for senescent cells is the lack of DNA replication, which is detected by 
the absence of proliferative markers, such as Ki67, PCNA or BrdU incorporation. Some 
senescent cells also display condensed heterochromatic regions, known as senescence-associated 
heterochromatic foci (SAHF). These foci are detected by DAPI staining, and enriched with 
certain histone modifications (H3 Ly9 methylation) and heterochromatin protein-1 (HP-1). 
Senescent cells also express proteins that are associated with DNA damage (e.g. phosphorylated 
H2AX (γH2AX) or p53-binding protein-1 (p53BP1)). Other markers, which represent the 
characteristics of senescent cells include the activation of immune surveillance-related genes and 
possible regulators for their pro-survival response (decoy receptor 2 (DCR2), p-Akt, p-Erk) (101, 
102, 105, 106). Recent studies also identified the down regulation of Lamin B1 in senescent cells 
(107). Metabolically active senescent cells communicate with neighboring cells and modify the 
extracellular matrix through a plethora of secretory factors, including cytokines and chemokines 
with proinflammatory properties, as well as various growth factors and proteases collectively 
known as senescence-associated secretory phenotype (SASP) (108). The activation of pathways 
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that mediate the regulation of these secretory phenotype appears to be NFκB and p38 (109). SA-
β-gal along with the presence of several such markers clearly indicates the presence of senescent 
cells.     
       
Figure 1.8: Hallmarks of senescence. A combination of markers representing different categories is 
necessary for the identification of senescent cells. 
 
1.3.3 Physiological impact of cellular senescence 
Senescent cells have been associated with diverse functions and impinge on fundamental 
biological processes that can have both beneficial and detrimental effects (Fig. 1.9).  
Tumor suppression: Over the past decade, studies of human tissues and cancer-prone mice 
clearly demonstrate that cellular senescence prevents tumorogenesis (110-112). In response to 
various transforming stimuli such as activated oncogenes, cancer cells must acquire a greatly 
expanded growth potential, a trait that is suppressed by senescence (17). Further, the senescent 
program activates two powerful tumor suppressor pathways (p53 and pRb-p16
INK4A
), which limit 
tumorigenesis in a cell autonomous manner (91, 92). Accordingly, in premalignant human nevi 
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and colon adenoma the detection of senescent cells is accompanied with markedly diminished 
malignant progression (113). Likewise, in mouse models with oncogenic Ras expression or Pten 
deletion, senescent cells were detectable in the premalignant tissues (110, 111, 114). In addition, 
there is evidence for the induction of senescence in response to chemotherapy or after 
reactivation of p53 (115, 116). In these cases, senescent response elicits an inflammatory 
response through SASP factors, which eliminates the senescent cells and confers tumor 
regression (117, 118).    
Limiting tissue damage: Senescence has also been shown to limits tissue damage following 
short-term injury and facilitates its repair through SASP expression. This comprehensive role 
was demonstrated in two recent studies. In a mouse model for liver damage, upon acute liver 
injury, hepatic stellate cells proliferate and secrete extracellular matrix (ECM) components, 
which produce a fibrotic scar (119). In this model, senescent cells limit fibrosis due to the 
enhanced secretion of ECM degrading proteins. In another mouse model, cellular senescence 
limits tissue damage at sites of cutaneous wound healing (120). 
Promoting embryonic development: Senescent cells are essential in mammalian embryonic 
development. Embryonic senescent cells share several features of OIS, including expression of 
p21 and SASP, which is necessary for the normal placental function. However, these senescent 
cells do not display a DDR but exhibit activation of TGFβ and PI3K pathways (103, 121). This 
developmentally programmed senescence is followed by macrophage mediated clearance and 
tissue remodeling.  
1.3.4 Pathological impact of cellular senescence 
Recent studies have shown that the accumulation of senescent cells is related to age-associated 
diseases and tumor promotion. Thus, senescence can be viewed as a double edged sword with 
both beneficial and deleterious effects (122, 123).  
Impairment of tissue integrity and function: In vivo as well as in vitro studies have provided 
convincing evidence that accumulation of senescent cells contributes to the overall decline in 
tissue regenerative potential that occurs with ageing and is associated with reduced stem-cell 
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proliferation capacity (124, 125). Recently, a seminal study by Baker et al. in transgenic mice, 
which lack p16
INK4A 
expressing cells provides further evidence that senescent cells are important 
drivers of multiple age-related pathologies (126). In addition, SASP factors secreted by 
senescence cells could act to disrupt the local stem-cell niche in a non-autonomous manner 
(127). SASP factors have the potential to negatively impact their surrounding microenvironment 
by cleaving membrane-bound receptors, signaling ligands, extracellular matrix and inducing 
EMT (96, 128). However, recent evidences demonstrate that activation of EMT is linked to the 
suppression of senescence (129). Taking together, promiscuous gene expression in senescent 
cells contributes to impairment in the cellular function and critically contributes to common 
pathologies such as, Alzheimer’s disease, diabetes, obesity, atherosclerosis and liver cirrhosis 
(98).    
 
Figure 1.9: Biological impact of cellular senescence. Metabolically active senescent cells secrete 
soluble and insoluble proteins as well as other factors collectively termed the SASP. These secretory 
factors reinforce the senescence proliferation arrest and also involved in the initiation of immune 
surveillance and clearance of senescent cells. Thus, short-term presence of senescent cells noted to be 
beneficial for tumor suppression, wound healing and embryonic development. However, long-term 
persistence of senescent cells is increasingly thought to play a role in tumor progression and age-related 
diseases. Modified from Burton et al. 2014 (101).  
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Tumor promotion: Senescence-inducing (p53-p21 or pRb-p16
INK4A 
pathways) stimuli are 
potentially oncogenic, and cancer cells acquire mutations in these pathways that allow them to 
bypass senescence, a crucial step in the development of cancer (91). Seemingly paradoxical, 
tumor-promoting role of senescence can be explained by the fact the senescent cells are able to 
promote malignancy in the cells around them. Accordingly, senescent cells co-cultured with 
tumor cells secrete SASP factors, which strikingly affect the behavior of neighboring cells to 
facilitate tumor growth (108). Furthermore, xenotransplantation of senescent cells with fully 
malignant cancer cells have shown to accelerate the tumor formation in mice (115, 130, 131). 
Thus, paracrine activities of many SASP proteins create a tissue microenvironment, which 
induce EMT and the invasiveness of premalignant cells (128).   
1.4 Aims of the study 
An increasing body of experimental evidence indicates a critical role of MYBBP1A in cellular 
senescence. First, MYBBP1A has been shown to regulate the activity of two key players in 
cellular senescence, namely p53 and RelA/p65 a subunit of NFκB, by direct physical interaction 
(78, 132). Second, Mori and colleagues demonstrated that loss of MYBBP1A affects expression 
of genes involved in cell cycle control and DNA damage, some of which are also implicated in 
cellular senescence (75). However, the regulation and function of MYBBP1A in the 
development and maintenance of cellular senescence as well as the clinical relevance of 
senescent tumor cells in HNSCC patients have not been addressed so far. Therefore, aim to 
investigate whether MYBBP1A function is implicated in cellular senescence using cell culture 
model of genotoxic senescence as a functional screening system. 
For this purpose, following questions were addressed: 
 What is the functional contribution of MYBBP1A in initiation and maintenance of 
genotoxic-induced senescence? 
 What is the clinical relevance of senescent tumor cells in a retrospective cohort of 
HNSCC patients? 
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2 Materials  
2.1 Equipment’s and Consumables 
EQUIPMENTS AND CONSUMABLES COMPANY 
1.5 ml, 2 ml Reaction Tubes Eppendorf, Hamburg 
2 ml Cryotubes Nunc 
Adhesion slides Super Frost® Plus Menzel-Gläser, Braunschweig 
AEC+ Substrate-Chromogen, Ready-to-Use Dako Cytomation, Hamburg 
AlphaMetrix tissue punch AlphaMetrix Biotech, Rodgau 
Autoclave VX95 Systec GmbH, Wettenberg 
Binocular Plan APO 1.0x Leica, Wetzlar 
Casy cell counter Roche, Mannheim 
Cell culture sterile hood Hera Safe Thermo Fisher Scientific, USA 
Cell incubator Binder, Tuttlingen 
Cell scraper TPP, Switzerland 
Centrifuge 5417R Eppendorf, Hamburg 
Centrifuge Biofuge 13 Hereaus Instruments, Hanau 
Centrifuge Varifuge 3.0R Hereaus Instruments, Hanau 
Cooling centrifuge 5403, 5415R Eppendorf, Hamburg 
Compact Mini-Centrifuge Hecht, Sondheim 
Cover slips (24x36 mm and 24x50 mm) Knittel, Bielefeld 
Cryo freezing container Thermo Fisher Scientific, USA 
Cryo vials (1.8 ml) Steinbrenner, Wiesenbach 
DAKO Pen Dako A/S Glostrup, Denmark 
Developer Classic E.O.S Agfa, USA 
Disposable scalpel Feather, Osaka (Japan) 
Dumont forceps Fine Science Tools, Heidelberg 
Electrophoresis chamber for agarose gels Buddenberg, Mannheim 
Electrophoresis chamber for SDS-PAGE Bio-Rad Laboratories, Munich 
Epi Chem II Darkroom (Gel documentation) UVP, Upland (CA, USA) 
Eppendorf research pipettes Eppendorf, Hamburg 
Filtertips Biozym Scientiﬁc, Oldendorf 
Fluoreszenzmikroskope BX50F Olympus Microscopy, Hamburg 
Freezer Liebherr, Ochsenhausen 
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Freezer -80°C Harris/Theromo Scientiﬁc 
Fridge 4° Liebherr, Ochsenhausen 
Gel documentation system Peqlab Biotechnology, Erlangen 
Glass beakers Fisherbrand, Schwerte 
Hamamatsu NanoZoomer Scanner Hamamatsu Photonics GmbH 
Ice-machine AF20, Scotsman 
Kryostat/Microtome blades C35 Feather, Osaka (Japan) 
Kryotome 2800 Frigocut Leica, Nussloch 
Magnetic stirrer/heat plate Ika® RH basic   Sigma-Aldrich, USA 
Magnetic stirrer/heat plate Variomag Monotherm H+P Labortechnik, München 
Magnetic stirrer/heat plate MR 3001K Heidolph, Schwabach 
MicroAmp® 96-well optical adhesive film Applied Biosystems, Foster City, 
CA 
MicroAmp® fast optical 96-well reaction plate Applied Biosystems, Foster City, 
CA 
Microplate Reader 680 Bio-Rad Laboratories, Munich 
Microscope BX-50F Olympus, Hamburg 
Microscope IX51 Olympus, Hamburg 
Microwave Robert Bosch GmbH, Stuttgart 
Milli-Q Millipore, Bedford (MA, USA) 
MJ Mini Gradient Thermal Cycler Bio-Rad Laboratories, München 
Nanodrop Spectrophotometer, ND-1000 PeqLab, Erlangen 
Needles (25G, 26G, 27G) Braun, Melsungen; TERUMO, 
Belgium 
Nuclease free reaction caps (safe-lock) Eppendorf, Hamburg 
PCR Cycler MJ Mini
TM
 Bio-Rad Laboratories, Munich 
PCR stripes (8x0,2ml) NerbePlus, Wiensen/Luhe 
PCR-Thermocycler (Gene Amp System 2400) Perkin Elmer, Wellesley (MA, 
USA) 
pH-meter WTW, Weilheim 
Pipettes Gilson-Abimed, Düsseldorf 
Pipettips Micro-Bio-Tec Brand, Giessen 
Pipettor Pipetboy acu Brand, Wertheim 
Platform shaker Polymax 1040 Heidolph, Schwabach 
Power supply Power Pac 300/3000 Bio-Rad Laboratories, München 
Precision scales Sartorius, Göttingen 
Reaction caps (1,5 ml and 2 ml) Eppendorf, Hamburg 
Rotator Rotoshake Genie® Scientific industries, USA 
Scales Sartorius, Göttingen 
SC30 (BF camera) Olympus, Hamburg 
Steam-cooker Braun, Kronberg 
StepOnePlus™ Real-Time PCR System Applied Biosystems, Foster City, 
CA 
Thermomixer Eppendorf, Hamburg 
Tissue Tek VIP 5 Jr Sakura, USA 
Trucount 15 ml, 50 ml Tubes Falcon, Greiner, Nunc 
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Vortex “Reax 2000” Heidolph, Kehlheim 
Water baths GFL M&S Laborgeräte 
Western blot imaging system FluorChem Q Biozym, Hessisch Oldendorf 
Western blot membrane Optitran BA-S83 Whatman, Dassel 
Wet blotting transfer system Bio-Rad Laboratories, Munich 
Whatman 3MM paper GE Healthcare, Dassel 
X-ray films Fuji, Düsseldorf 
XM10 (black/white camera) Olympus, Hamburg 
2.2 Chemicals 
COMPONENT COMPANY 
10x PCR buﬀer Genaxxon, Biberach 
Acetic acid  Merck, Darmstadt 
Acetone Fisher Scientific, UK; Sigma, Taufkirchen 
Acrylamid/Bisacrylamid (30:0.8) Roth, Karlsruhe 
Agarose Roth, Karlsruhe 
Ammonium peroxodisulfate (APS) Sigma, Taufkirchen 
β-Mercaptoethanol Merck, Darmstadt 
BCA reagents Thermo Scientiﬁc, USA 
Biotyinylated secondary antibody Vector Laboratories, Burlingame, USA 
Boric acid Roth, Karlsruhe 
Bovine serum albumine, fraction V PAA, Pasching, Austria 
Bromphenol Blue Sigma Aldrich, München 
Calcium chloride (CaCl2) Merck, Darmstadt 
Dimethylsulfoxide (DMSO) Merck, Darmstadt 
Disodium hydrogen phosphate (Na2HPO4x2H2O) Merck, Darmstadt 
Dithiothreitol (DTT) AppliChem, Darmstadt 
ECL reagent solutions AppliChem, Darmstadt 
EDTA AppliChem, Darmstadt 
Eosin Roth, Karlsruhe 
Ethanol p.a. Merck, Darmstadt 
Ethanol, denaturated 99,7% Roth, Karlsruhe 
Ethanolamine Merck, Darmstadt 
Ethidiumbromide AppliChem, Darmstadt 
Ethylenediamine-tetraacetate (EDTA) Roth, Karlsruhe 
Eukitt Kindler, Freiburg 
Formaldehyde 37% Sigma Aldrich, München 
GelRed Biotium, Hayward, CA 
Glycerol AppliChem, Darmstadt 
Haematoxylin AppliChem, Darmstadt 
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Hematoxylin according to Gill II Roth, Karlsruhe 
Hoechst 33342 Biomol, Hamburg 
Hydrochloric Acid Merck, Darmstadt 
Hydrogen peroxide Merck, Darmstadt 
Isopentan Roth, Karlsruhe 
Isopropanol Roth, Karlsruhe 
Methanol Merck, Darmstadt 
MgCl2 Genaxxon, Biberach 
Microplate Reader Model 680 Bio-Rad Laboratories, München 
Milk powder Roth, Karlsruhe 
MnCl2 Roth, Karlsruhe 
N, N, N‘, N‘, Tetramethyl ethylenediamine 
(TEMED) 
Roth, Karlsruhe 
NaH2PO4xH2O Merck, Darmstadt 
Natrium chloride Roth, Karlsruhe 
Natrium-deoxycholat AppliChem, Darmstadt 
NP-40 Sigma Aldrich, München 
Oligo-dT primers Fermentas, St. Leon-Rot 
Paraﬃn Vogel, Giessen 
Potassium Chloride Roth, Karlsruhe 
RNase-free water   Ambion, Life Technologies, Frankfurt 
Sodium Chloride Roth, Karlsruhe 
Sodium Citrate Roth, Karlsruhe 
Sodium hydroxide Merck, Darmstadt 
Sodiumdodecylsulfate (SDS) Gerbu Biotechnik, Gaiberg; Roth, KA 
Tris HCl Roth, Karlsruhe 
Tris-base Roth, Karlsruhe 
Triton X-100 AppliChem, Darmstadt 
Tween 20 AppliChem, Darmstadt 
Xylol AppliChem, Darmstadt 
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2.3 Molecular biology reagents  
 COMPONENT COMPANY 
Agilent RNA 6000 Nano Kit Agilent Technologies, Böblingen 
AKT Inhibitor V, Triciribine Calbiochem (EMD Millipore) 
BCA protein assay reagent Thermo Scientific, USA 
BrdU (5-bromo-2-deoxyuridine) BD Pharmingen, Germany 
Cell lysis buffer NEB, UK   
DAB kit Vector Laboratories, Burlingame, USA 
DNaseI Digest Kit Qiagen, Hilden 
dNTPs GeneOn, Ludwigshafen 
GelRed® DNA stain Genaxxon, Biberach 
GeneRuler 100bp DNA ladder Fermentas, St. Leon-Rot 
GeneRuler DNA ladder mix Fermentas St. Leon-Rot 
ImmPRESS Anti-Rabbit Vector Laboratories, Burlingame, USA 
Lipofectamine™ 2000 Invitrogen, Karlsruhe 
miRNeasy Mini Kit Qiagen, Hilden 
MG132 Sigma Aldrich, USA 
MultiScribe™ reverse transcriptase Applied Biosystems, Foster City, CA 
Oligo-dT primers Fermentas, St. Leon-Rot 
PCR buﬀer S Genaxxon, Biberach 
PeqGOLD protein marker IV, pre-stained PeqLab, Erlangen 
Phosphatase inhibitor 1 + 2   Sigma, Taufkirchen 
PI3 Kinase Inhibitor (LY294002) Cell signaling, Germany 
Power SYBR® Green PCR master mix   Biosystems, Foster City, CA 
Proteinase K Applied Gerbu, Heidelberg 
dNTPs Fermentas, St Leon Roth 
RNeasy Mini Kit Qiagen, Hilden 
RNase-free DNase Set Qiagen, Hilden 
Riboblock RNase inhibitor Fermentas, St. Leon-Rot 
Revertaid M-MuLV Buﬀer Fermentas, St. Leon-Rot 
Revertaid M-MuLV Reverse Transcriptase Fermentas, St. Leon-Rot 
Senescence β-Galactosidase Staining Kit Cell signaling Technology, Germany 
Taq polymerase Genaxxon, Biberach 
Vectastain Elite-ABC-Peroxidase Vector Laboratories, Burlingame, USA 
         
         All kits and reagents were used according to the manufacturer’s protocol unless otherwise stated. 
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2.4 Buffers and solutions 
Blocking reagent for histology 0.1 % BSA, 5 % host serum in PBS 
 
10x Citrat Buﬀer 1.8 mM citric acid, 8.2 mM sodium citrate 
 
6x DNA loading buﬀer 0.25 % (v/v) Bromphenol blue, 0.25 % (v/v) 
Xylene Cyanol, 30 % (v/v) glycerol 
 
4 % formaldehyde 4 % (v/v) formaldehyde in PBS 
 
4x Laemmli buffer 250 mM Tris-HCl pH 6.8, 8 % (v/v) SDS, 40 % 
(v/v) glycerol, 500 mM DTT, bromphenolblue 
  
NP-40 lysis buffer 150 mM NaCl, 50 mM Tris-HCl, pH 7.4, 1 % NP-
40, 10 mM EDTA, 10 % glycerol, freshly added 
1:100 v/v protease inhibitors 
  
Mowiol 6 g glycerol, 2.4g Mowiol 4-88, 6 ml H2O 
 
Separation gel 10-15 % acrylamide/bisacrylamide, 375 mM Tris-
HCl pH 8.8, 0.1 % SDS, 0.1 % APS, 0.1 % 
TEMED 
  
Stacking gel 4 % acrylamide/bisacrylamide, 125 mM Tris-HCl 
pH 6.8, 0.1 % SDS, 0.1 % APS, 0.1 % TEMED 
  
Stripping solution 15 g glycine, 1 % SDS, 10 ml Tween-20, adjusted 
to pH 2.2 with 37 % HCl, add 1l H2O 
  
10 x PBS 1.37 M NaCl, 27 mM KCl, 82 mM Na2HPO4 x 2 
H2O, 17 mM NaH2PO4 x H2O 
 
10x SDS running buffer 250 mM Tris-base, 1.92 M glycine, 1 % (v/v) SDS  
  
10x TBE 1 M Tris, 1 M boric acid, 20 mM EDTA 
10x TBS 61 g Tris base, 160 g NaCl, ad 1 l H2O, adjusted to 
pH 7.6 
  
PCR reaction mix 1.1x PCR buﬀer S, 1.7 mM MgCl2, 220 µM dNTPs 
 
Western blot transfer buffer 25 mM glycine, 0.15 % (v/v) ethanolamine, 20 % 
(v/v) methanol 
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2.5 Antibodies 
   Primary Antibodies    
ANTIGEN HOST DILUTION SORUCE 
β-Actin Mouse 1:10000 Sigma-Aldrich/A5441 
AKT Rabbit 1:1000 Cell Signaling/CS-9272 
phospho- AKT (Ser473) Rabbit 1:1000 Cell Signaling/CS-4060 
phospho- AKT (Thr308) Rabbit 1:1000 Cell Signaling/CS-4056 
Caspase-3 Rabbit 1:1000 Cell Signaling/CS-9665 
γ-H2AX Rabbit 1:400 (IF) Cell Signaling/CS-9718 
MYBBP1A Rabbit 1:1000 Abcam/Ab-54160 
MYBBP1A  Rabbit 1:100 (IF) Abcam/Ab-99361 
p21(CDKN1A) Mouse 1:1000(WB) BD Pharmingen/556431 
  1:50(IF)  
    Secondary Antibodies 
ANTIGEN HOST DILUTION LABEL SORUCE 
Mouse goat 1:5000 HRP Cell Signaling/CS-7076 
Rabbit  goat 1:5000 HRP Cell Signaling/CS-7074 
Mouse donkey 1:200 Cy3 Dianova 
Rabbit donkey 1:200 Alex488 Dianova 
Rabbit goat 1:500 biotin Vector, (BA-100) 
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2.6 Oligonucleotides 
PRIMER  SEQUENCE TA 
β-Actin for CCAACCGCGAGAAGATGA 60˚C 
 rev CCAGAGGCGTAGAGGGATAG  
MYBBP1A for CGCACCACCTGTGCCGTGCCCGGCG 60˚C 
 rev CTTGGTCAGGAAGGAGCTCAGTGCT  
IL-6 for GAAAGCAGCAAAGAGGCACT 60˚C 
 rev TTTCACCAGGCAAGTCTCCT  
IL-8 for TTGGCAGCCTTCCTGATTTC 60˚C 
 rev TCTTTAGCACTCCTTGGCAAAAC  
IL-1β for CCACAGACCTTCCAGGAGAATG 60˚C 
 rev GTGCAGTTCAGTGATCGTACAGG  
TGF-β1 for TGGTGGAAACCCACAACGAA 60˚C 
 rev GAGCAACACGGGTTCAGGTA  
2.7 siRNA and Plasmids 
NAME COMPANY 
Control siRNA Santa Cruz/sc-37007 
MYBBP1A siRNA(h) Santa Cruz/sc-396003 
pcDNA3.1  Invitrogen, Germany 
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2.8 Cell culture 
Cell culture media and supplements 
Dulbecco‘s Modified Eagles Medium (DMEM) PAA Laboratories, Austria 
Fetal calf serum (FCS) Sigma Taufkirchen 
L-Glutamine  PAA Laboratories, Austria 
Penicillin/Strptomycin PAA Laboratories, Austria 
Trypan blue Fluka, Neu-Ulm 
Trypsin PAA Laboratories, Austria 
Opti-MEM
® 
I Reduced Serum Medium Gibco, Life Technologies 
 
Cell lines 
NAME DESCRIPTION SOURCE 
FaDu Human hypopharyngeal carcinoma ATCC 
Cal-27  Human oral adenosquamous carcinoma ATCC 
HeLa Human cervix adenocarcinoma ATCC 
SCC-25 Human oral squamous carcinoma of the tongue ATCC 
2.9 Human tissue blocks 
Tumor specimens for tissue micro array analysis were obtained from OPSCC patients treated at 
the University Hospital Heidelberg between 1990 and 2008. Paraffin-embedded tissue specimens 
from OPSCC patients were provided by the tissue bank of the National Center for Tumor 
Disease (Institute of Pathology, University Hospital Heidelberg) after approval by the local 
institutional review board (ethic vote 206/2005). Clinical and follow-up data for all patients were 
provided by the Department of Otolaryngology, Head and Neck surgery, at the University 
Hospital Heidelberg. Only tissue samples of primary tumors were included in the present study. 
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2.10 Software 
 
 
 
PROGRAME DISTRIBUTOR 
Adobe Acrobat 9.0; Photoshop CS5; Illustrator CS5 Adobe, San Jose, USA 
CellSens Dimension 1.5 Olympus, Hamburg 
EasyControl 2.04 for Epi Chem II darkroom UVP, Upland (CA, USA) 
Endnote v. X7 Adept Scientific GmbH, Frankfurt 
Mendeley Desktop 1.7.1 Mendeley Ltd., London, UK 
Hamamatsu NanoZoomer (NDP-Viewer) Hamamatsu Photonics, Herrsching 
Image J W. Rasband, National Institutes of 
Health, Maryland, USA 
IBM SPSS Statistics 20 IBM Corporation, Somers NY, USA 
Microsoft Oﬃce 2007 Microsoft Corporation 
Microsoft Windows XP Microsoft Corporation 
Nikon NIS-Elements 3.20.02 Nikon 
Sigma Plot v. 12.5 Systat Software Inc. Washington, 
USA 
StepOne Software v. 2.2.2 Life Technologies, Darmstadt 
                                                                                   32                                     MATERIALS AND METHODS         
 
3 Methods  
3.1 Protein biochemistry methods 
3.1.1 Preparation of protein extracts 
Protein extraction was performed on cultured cells. Pelleted cultured cells were lysed by ice-cold 
RIPA buffer (50 mM Tris-HCl pH 8.0, 150 mM NaCl, 0.1% SDS, 0.5% (v/v) deoxylacid Na
+
-
salt, 1% (v/v) NP-40) with freshly added protease inhibitor and phosphatase inhibitor cocktail 
(1:100) (Sigma-Aldrich, Germany). Then samples were incubated for 10 min on ice and 
centrifuged for 10 min at 13000 rpm at 4 ˚C (Centrifuge 5403, Eppendorf). The supernatant was 
collected and stored at -80 ˚C. One aliquot was taken for determination of protein concentration 
in the lysate.  
3.1.2 Determination of protein concentration 
Protein concentration in RIPA lysates was determined using the BCA protein assay kit (Thermo 
Scientific) according to the user’s manual.  
3.1.3 SDS polyacrylamide gel electrophoresis (SDS-PAGE) 
Sodiumdodecylsulfate-polyacrylamide gel electrophoresis (SDS-PAGE) was performed to 
separate proteins according to their molecular weight. The SDS-PAGE is composed of a stacking 
(4% Acrylamide/Bisacrylamide, 125 mM Tris-HCl pH 6.8, 0.1% SDS, 0.1% APS, 0.1% 
TEMED) and a separation gel (10-15% Acrylamide/Bisacrylamide, 375 mM Tris-HCl pH 8.8, 
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0.1% SDS, 0.1% APS, 0.1% TEMED). The percentage of the separation gel was adapted 
according to the size of the target proteins. Equal amounts of protein samples (20 μg) were 
mixed with 4xLaemmli buffer containing 4% β-Mercaptoethanol and incubated at 95 ˚C for 5 
min until loaded onto the gel. The gel run was performed in 1x SDS running buffer at 25-35 mA. 
For protein size estimation, a pre-stained protein marker (PeqGOLD protein marker IV, PeqLab) 
was run on parallel to the samples.  
3.1.4 Transfer of proteins to nitrocellulose membranes 
(Western blot) 
Denatured proteins separated by the SDS-PAGE were transferred onto nitrocellulose membranes 
(Optitran BA-S83) using a wet-blotting system from Bio-Rad. The pre-assembled blot comprised 
of separation gel and nitrocellulose membrane embedded in three sheets of Whatman 3MM 
paper on either side was pre-incubated in Western blot transfer buffer (25 mM glycine, 0.15% 
ethanolamine, 25% (v/v) methanol). The transfer was carried out for 1 - 1.5 h in Western blot 
transfer buffer at a constant voltage of 100 V. Following transfer, the membrane was incubated 
in 5 % BSA or milk in PBS-T (PBS-0.5% Tween) for 30 min at RT while shaking in order to 
block unspecific binding of the antibodies. The membrane was incubated with the diluted 
primary antibody (in blocking buffer) o/n at 4°C. The membrane was washed at least three times 
with PBS-T for 10 min while shaking. Finally, the membrane was incubated with the diluted 
secondary antibody coupled to horse radish peroxidase (HRP) (in blocking buffer) for 1 h at RT. 
Subsequently, the membrane was washed as before and incubated for 1 min with the enhanced 
chemiluminescence solution (Thermo Scientific). The signals were detected by exposing the 
membrane to a X-ray film in the dark followed by incubation in the Classic E.O.S developer 
(Agfa). All antibodies used for Western blot analysis are listed in section 2.5.  
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3.2 Molecular biology methods 
3.2.1 Isolation of total RNA 
Total RNA was isolated from cultured cells using RNeasy Mini Kit (Qiagen) according to the 
manufacturer’s instructions.    
3.2.2 Measurement of RNA quantity and quality  
Quality and quantity of isolated RNA were assessed using a Nanodrop Spectrophotometer (ND-
1000 UV-VIS, PeqLab) according to the manufacturer’s instructions. Purity of extracted RNA 
and contamination by proteins and aromatic compound was determined using the OD 260/280 
and the OD 260/230 ratio. The ratio of the sample of absorbance with OD 260/280 of 1.8-2.0 and 
OD 260/230 absorbance ratio greater than 2.0 were accepted and used for further analysis. 
3.2.3 cDNA synthesis  
5 μg total RNA was reverse transcribed into cDNA using reverse transcriptase. Therefore, RNA 
was diluted in 35 μl nuclease-free H2O and 0.5 μl of Oligo (dT) 18 primer (100 μM, Fermentas). 
RNA was denatured at 70 ˚C for 5 min followed by 5 min at 4 ˚C. Subsequently, a reaction mix 
containing 10 μl 5x RevertAid buffer, 2 μl 25 mM dNTP mix, 2 μl RiboLockTM RNase Inhibitor 
(40 U/μl, Fermentas) and 0.5 μl RevertAidTM M-MuLV reverse transcriptase (200 U/μl, 
Fermentas) were added to reach a final volume of 50 μl. The reaction was incubated for 1 h at 42 
˚C. Obtained cDNA was stored at -20 ˚C.   
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3.2.4 Amplification of DNA by polymerase chain reaction 
(PCR)  
Polymerase chain reaction (PCR) amplification was routinely performed for semi-quantitative 
analyses of gene expression or the detection of specific genomic loci. For this, 15 ng cDNA or 3 
μl of genomic DNA (10-500 ng) was mixed with 45 μl of PCR reaction mix (10 x PCR buffer S, 
1.7 mM MgCl2 (Genaxxon), 220 μM dNTPs (Fermentas), 0.2 μl of each primer (50 pmol/μl), 0.3 
μl Taq-plymerase S (Genaxxon) and ddH2O was added to a final volume of 50 μl). The PCR 
reaction was performed according to the following protocol: 
Initial Denaturation 94 ˚C 5 min  
Denaturation 94 ˚C 30 sec  
Primer hybridization TA ˚C 30 sec 25-40 cycles 
Elongation 72 ˚C 45 sec  
Final elongation 72 ˚C 5 min  
Hold 4 ˚C ∞  
 
Afterwards, the PCR reaction was analyzed by agarose gel electrophoresis (3.2.6). The specific 
annealing temperatures (TA) for the respective primers are listed in section 2.6.    
3.2.5 Quantitative real-time PCR (RQ-PCR) 
For relative quantification of target gene expression analysis, SYBR green-based real-time PCR 
was performed on the StepOnePlus
TM
 real-time PCR system (Applied Biosystems). Every PCR 
reaction was carried out in triplicates on a 96 well plate with 5 ng of cDNA in a final volume of 
20 µl containing 10 μl of Power SYBR® Green PCR Master Mix (Applied Biosystem) and 0.1 μl 
forward and reverse primers (50 pmol/μl each). Since AmpliTaq polymerase (present in Power 
SYBR
®
 Green PCR Master Mix) has an efficient elongation capacity already at 60 ˚C, a two-step 
cycling stage was generally sufficient (Stage 2). An additional elongation phase was only 
included when the amplified fragment was longer than 300 bp. Primer sequences and 
corresponding annealing temperatures are provided in Table 1.6. The following PCR program 
was used: 
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Stage 1 Cycle 1 94 ˚C 5 min 
Stage 2 (40x) Cycle 2 94 ˚C 30 sec 
  TA ˚C 30 sec 
  72 ˚C 30 sec 
Stage 3 Cycle 3 95 ˚C 15 sec 
 Cycle 4 60 ˚C 1 min 
 Cycle 5 +0.5 ˚C 15 sec (up to 95 ˚C)   
 
Data obtained from real-time PCR were analyzed using the StepOne
TM
 software v2.2 (Applied 
Biosystems). Target gene (GOI, gene of interest) cycle of threshold (CT) values was normalized 
to the corresponding CT values of housekeeping genes (HKG), i.e. β-Actin using the ∆CT 
method. Primer specificity was determined by melt curve analysis and amplicon size verification 
by agarose gel electrophoresis (2.2.6). Primer efficiency was measured by analyzing consecutive 
dilution series of reference cDNAs ranging from 25 ng to 0.1 ng and was included into the 
calculation of fold induction.  
EffGOI 
Ref(GOI)-Sample(GOI)
  
EffHKG 
Ref(HKG)-Sample(HKG)
 
=Fold Induction 
3.2.6 Agarose gel electrophoresis  
DNA fragments generated by conventional or semi-quantitative PCR reactions were separated 
according to their molecular size by agarose gel electrophoresis. For fragments between 100 bps 
and 400 bps a 2 % agarose gel in 1x TBE buffer by boiling in a microwave was prepared and 
intercalating DNA dye GelRed
®
 DNA stain (Genaxxon) was added  in a 1:20,000 ratio. Prior to 
loading, DNA samples were mixed with 6x loading buffer and the liquid gel was poured into the 
gel chamber. GeneRuler™ DNA Ladder Mix (0.1 - 10.0 kbp, Fermentas) or 100 bp DNA Ladder 
(100 - 1000 bp, Fermentas) were used as a reference to define the size of the specific fragments 
and separation was performed in 1xTBE buffer at constant voltage (120 V). Bands were 
visualized under UV light and photographed.    
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3.3 Cell culture 
3.3.1 Cultivation of cell lines and treatment 
Human HNSCC cell lines and HeLa were purchased from ATCC. Cells were maintained in 
Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% fetal bovine serum 
(Invitrogen, Germany), 2 mM L-Glutamine (Invitrogen, Germany) and Antibiotics (50 µg/ml 
Pencillin-Streptomycin, Invitrogen, Germany) in a humidified incubator of 6% CO2 at 37º
 
C. To 
avoid mycoplasm contamination, mycoplasm tests were performed routinely by PCR analysis 
using the PromoKine Mycoplasma PCR detection Kit. For passaging, cells were trypsinized with 
1 ml Trypsin/EDTA (0.2% Trypsin in PBS/EDTA) after reaching a confluency of 80-90%. 
Trypsin reaction was stopped with medium and trypsinized cells transferred to a Falcon tube. 
Following centrifugation for 3 min at 1000 rpm (Megafuge 1.0, Heraeus), the cell pellet was 
resuspended in the appropriate amount of media and counted in a cell counter. The cell number 
needed was plated on new cell culture dishes. To freeze cells, 1x10
6
 cells were frozen in 1.5 ml 
freezing medium (10% DMSO in FCS). For long-term storage, cells were stored in liquid 
nitrogen. 
Unless otherwise indicated, cells were challenged in the absence or presence of 10 µM of 
etoposide (Sigma-Aldrich, Germany) for the indicated time period to induce DNA damage.  
3.3.2 Transient transfection of cell lines 
In all cases cells were trypsinized 24 hours before transfection and seeded on a 6-well cell 
culture plate (3x10
5
/ well). The transfection of FaDu and HeLa cell lines was performed using 
Lipofectamine
TM
 2000 (Invitrogen, Germany) according to manufacturer´s instructions. Prior to 
transfection, cell media was changed with Opti-MEM
® 
I reduced Serum Media (Invitrogen), 
which was again replaced with normal growth media 4-6 hours after transfection. Analyses of 
MYBBP1A silencing and ectopic overexpression were done 48 hours after transfection.  
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3.3.3 BrdU incorporation assay 
Cell proliferation was analyzed using the BrdU (5-bromo-2-deoxyuridine) Flow Kit (BD 
pharmingen, Germany) according the manufacturer’s instructions. BrdU quantification was 
performed using ImageJ software. Total cells were quantified by counterstaining with Hoechst 
33342 (Sigma-Aldrich, Germany).     
3.3.4 Senescence-associated β-galactosidase (SA-β-gal staining) 
Cells were fixed in fixation buffer and SA-β-galactosidase assay was performed using a 
Senescence β-Galactosidase Staining Kit (Cell Signaling Technology, Germany) in accordance 
with the manufacturer´s instructions. Senescence induction was quantified by ImageJ software 
upon staining of the nuclei with Hoechst 33342 (Sigma-Aldrich, Germany) and is given as 
relative amount of positive cells.   
3.3.5 Clonogenic survival assay 
Radioresistance was measured by a colony formation assay following exposure to irradiation. 
FaDu cells were transfected with scramble or MYBBP1A specific siRNAs and 48 hours post-
transfection, 1000 cells were seeded in 6 well plates. Cells were exposed to a radiation dose of 5 
Gy. Irradiated cultures and non-treated controls were incubated for 10 days, fixed with methanol 
and stained with 1% crystal violet. Stained clones were rinsed twice with water, dried and 
counted. The survival fraction was calculated according to the number of colonies divided by the 
number of cells seeded.  
3.3.6 Immunofluorescence (IF)  
Cells were grown on sterile coverslips and fixed with phosphate-buffered saline (PBS) - 4% 
paraformaldehyde for 15 min at room temperature. After being washed with PBS, the cells were 
permeabilized with 0.5%Triton X-100 buffer in PBS and blocked with PBS-1% bovine serum 
albumin-0.2% Tween 20 for 30 min at room temperature. Coverslips were incubated with 
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primary antibody in blocking buffer (PBS-1% bovine serum albumin-0.2% Tween 20) for 2h. 
The coverslips were rinsed with PBS and then incubated with fluorochrome-conjugated 
secondary antibody. Cells were washed again with PBS, counterstained with Hoechst 33342 
(Sigma-Aldrich, Germany) and visualized by fluorescence microscopy. All antibodies used for 
the analysis are listed in section 2.5. 
3.4 Histology methods 
3.4.1 Preparation of paraffin-tissue sections 
Sections from paraffin-embedded tissue were prepared by cutting the paraffin blocks in 6 μm 
slices with the microtome RM2155. The sections were then dried at 42 ˚C o/n and stored at room 
temperature. 
3.4.2 Immunohistochemistry (IHC)  
Immunohistochemistry analysis enables the detection of specific proteins on tissue sections with 
antibodies. First, the 5 µm tissue paraffin sections were deparafﬁnized in xylene for ten minutes 
and then rehydrated in a descending ethanol series (100%, 95%, 90%, 80%, 70%, 50%, 30% 
(v/v) ethanol in ddH2O, 2 min each). Endogenous peroxidase was blocked with 3 % H2O2 for 10 
min and heat-mediated antigen retrieval was performed in citrate buﬀer (pH 6) for 30 min in a 
steam-cooker, then cooled down for additional 10 min, and rinsed in tap water. Sections were 
washed with PBS and blocked in horse serum (ImmPress, VectorLaboratories, Burlingame, CA, 
USA) for 30 min to block unspecific binding sites. Subsequently, primary antibody was 
incubated in blocking buffer o/n at 4 °C in a wet chamber. Afterwards, sections were washed 
trice in PBS under agitation for 5 minutes and incubated with the corresponding, peroxidase 
coupled secondary antibody (ImmPress) for 30 min at RT. Subsequently, sections were washed 
once with PBS and incubated (1-5 min) with the DAB peroxidase substrate (brown staining 
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signal) (Vector Laboratries Inc., CA 94010, USA). Samples were counterstained with 
hematoxylin and washed with tap water for 10 min. The tissue sections were dehydrated in 
increasing percentage of ethanol for 10 seconds each (70%, 90%, 100%) and 2 min each in xylol. 
The sections were the mounted with Evanolor Eukitt (Kindler GmbH, Freiburg, Germany). All 
antibodies which were used IHC are listed in section 2.5. 
3.5 Human patient samples 
3.5.1 Tissue microarray (TMA) production  
Tissue microarrays containing multiple spots from primary OPSCC patients as well as healthy 
mucosa were generated as previously described (133). Tissue microarrays included a collection 
of 188 tumor biopsies of patients as well as healthy mucosa. Briefly, these biopsies were stained 
by hematoxyline and eosin (H&E) and stained sections were cut from each donor block to define 
representative tumor regions. Small tissue cylinders with a diameter of 0.6 mm were taken from 
selected areas of each donor block using a tissue chip microarrayer (Beecher Instruments) and 
transferred to a recipient paraffin block. The recipient block was subsequently incubated at 37 ˚C 
for 1 h. This block was cut in 5 μm paraffin sections with a cryostat at 20 ºC.  
3.5.2 TMA scoring  
TMAs were scanned using the Nanozoomer HT Scan system (Hamamatsu Photonics, Japan) 
following immunohistochemistry as described in 2.4.2. Three experienced observers analyzed 
scanned slides by using the NDP Viewer software (version 1.1.27). The semi-quantitative 
analysis was performed according to the number of stained tumor cells (score A: 1 = no positive 
cells, 2 = less than 33% positive cells, 3 = between 34% and 66%, 4 = more than 66% positive 
cells) and according to the staining intensity (score B: 1 = no staining, 2 = weak staining, 3 = 
moderate staining, 4 = high staining). Only primary tumors were included in the analysis and 
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scores from spots of the same patients were combined using the median value. Subsequently, the 
number of stained tumor cells (score A) and staining intensity (score B) were multiplied resulting 
in the final expression score (range 1–16). To determine the final activity score, a ratio 
(pAKT(Ser473) or pAKT(Thr308)/total AKT) was calculated. Patients were further divided in to 
two subgroups with MYBBP1A
low
pAKT
high
 (n=7) and all other combinations (n=54).   
3.5.3 Statistical analysis 
Statistical analysis was done using SPSS (Version 19) and SAS (Version 9.2) statistics software. 
Differences between the groups were assessed using Chi square test or Fisher’s exact test. Patient 
and tumor characteristics were obtained from clinical data. Clinical data were extracted from the 
electronic patient ﬁles of the university hospital Heidelberg and transferred to the laboratory 
database. The included data mainly refer to general information (yes/no) without quantitative 
data. The HPV status and viral transcript were determined as described previously (134). Pearson 
and Spearman’s correlation between score A and B were tested.  
 
Overall survival (OS) was calculated from registration date until date of OPSCC-related death, 
censoring patients alive at last follow-up and non–OPSCC-related deaths. Progression-free 
survival (PFS) was calculated from the date of primary tumor diagnosis to the date of the first 
local recurrence, lymph node or distant metastasis, second primary carcinoma or date of OPSCC-
related death within the follow-up period (events), or to the date of OPSCC-unrelated death or 
without progression (censored). Estimation of OS and PFS distributions were performed by the 
Kaplan-Meier method and differences between the groups were determined by log-rank tests 
(135). Multivariate Cox proportional hazard models were used to analyze the association 
between MYBBP1A
low
AKT
high
 expression scores and overall survival of OPSCC, together with 
covariates age (continuous variable), gender (female vs. male), clinical stage (IV vs. I-III), 
alcohol and tobacco consumption (never vs. former/current) and human papillomavirus (HPV) 
status (HPV active vs. inactive). No imputation methods for replacing missing values of the 
covariates were used. For all covariates, the validity of the proportional hazards assumption was 
tested with Schoenfeld residuals.  
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The results are expressed as means ± standard deviations (SD) of three independent experiments, 
each performed in triplicate. Statistical significance was determined using the Student´s t test; 
p<0.05 was considered significant. Statistical evaluation of obtained data was performed with 
SigmaPlot 11.0 (Systat Software Inc.).   
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4 Results 
An increasing body of experimental evidence indicates a critical role of MYBBP1A in cellular 
senescence. In order to investigate the regulation and function of MYBBP1A in the development 
and maintenance of cellular senescence the following topics were addressed: (a) expression of 
MYBBP1A in an established cell culture model of genotoxic senescence, (b) functional 
contribution of MYBBP1A in the initiation and maintenance of senescence by loss-of-function 
and gain-of function approaches, and (c) combinatorial analysis in a retrospective cohort of 
oropharyngeal SCC (OPSCC) patients by immunohistochemical staining to elucidate the clinical 
relevance of senescent tumor cells.  
4.1 Regulation and function of MYBBP1A during DNA 
damage-induced senescence in vitro 
To elucidate the role of MYBBP1A under conditions of DNA damage-induced senescence in 
tumor cells, an in vitro model for cellular senescence was established using the topoisomerase 
inhibitor etoposide (VP16), a commonly used anticancer drug (136).  
4.1.1 Etoposide induced morphological and biochemical 
features of senescence in vitro    
Recent publications have shown that low-dose etoposide-treatment induces irreversible DNA 
strand breaks accompanied by a senescent-like phenotype (119, 137-139). Accordingly, FaDu 
cells, a human HNSCC cell line, were treated with the clinically relevant concentration of 
etoposide (10 μM) for 24h and induction of senescence markers in addition to the enlarged 
morphology was investigated. Immunofluorescence microscopy revealed an accumulation of 
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DNA double strand breaks, which was monitored by persistent nuclear γH2AX staining at day 3 
after treatment (Fig. 4.1A). Cells also exhibited a significant decrease in cell proliferation as 
assessed by BrdU incorporation (Fig. 4.1B). Furthermore, a peak in cell death as determined by 
Caspase-3 processing was seen 2 days after etoposide treatment, but was absent at later time 
points (Fig. 4.1C). Western blot analysis also demonstrated a strong induction of the CDK 
inhibitor p21
CDKN1A
 following treatment, an early marker of cellular senescence (105). These 
observations strongly indicated that in response to DNA damage, a senescent-like state was 
induced.       
 
Figure 4.1: Etoposide induces DNA damage in FaDu cells. Cells were cultured in the absence or 
presence of 10 µM etoposide for 24 h to induce DNA damage. (A) 3 days post-treatment, persistent DNA 
damage was determined by immunofluorescence staining for γ-H2AX. (B) Decreased cell proliferation 
was assayed by BrdU incorporation and the relative percentage of BrdU-positive cells is given as mean 
value ± SD (n=3) of control and etoposide-treated cells at the indicated time points. (C) Whole cell lysate 
was extracted at the indicated time points and activation of apoptosis was determined by Caspase-3 
processing using Western blot analysis. The extracts were also immunoblotted for the senescence marker 
p21
CDKN1A
 using β-Actin as loading control for protein quality and quantity. White scale bar represents 50 
μm. 
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It is well established that senescent, but not pre-senescent or terminally differentiated cells stain 
positive for SA-β-gal (104). To investigate whether the previously observed irreversible cell 
cycle arrest was accompanied by senescence induction, cells were assayed for SA-β-gal activity. 
FaDu cells exhibited a significant increase in SA-β-gal activity relative to controls, 3 days post 
treatment, and the percentage of SA-β-gal positive cells continued to increase up to 65% at day 7 
(Fig. 4.2).  
 
Figure 4.2: DNA damage induces senescence in FaDu cells. Cells were cultured in the absence or 
presence of 10 µM etoposide for 24 h to induce DNA damage. (A) Efficient induction of senescence was 
analyzed by SA-β-Gal staining of control and etoposide-treated cells at the indicated time points post-
treatment. (B) Senescence induction was quantified and is given as relative amount of SA-β-Gal positive 
cells. Data are represented as mean ± SD (n=3). White scale bar represents 50 μm. Statistical analysis was 
performed using unpaired two-tailed t-test; ** p<0.01; *** p<0.001.  
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To further characterize the DNA damage-induced senescence phenotype, etoposide treated cells 
were examined for the induction of a ‘senescence–associated secretory phenotype’ or ‘SASP’. 
SASP is associated with the upregulation of distinct cytokines such as IL-6, IL-8, and most 
importantly IL-1β, which can mediate a positive feedback loop to maintain or amplify the effect 
of SASP (140). Quantitative RT-PCR analyses confirmed that expression of IL-6, IL-8 as well as 
IL-1β was upregulated after exposure to etoposide (Fig. 4.3). Thus, etoposide per se was able to 
induce senescence in FaDu cells, which was characterized by SASP and increased secretion of 
various cytokines.   
 
Figure 4.3: DNA damage-induced senescence initiates SASP. Cells were pre-treated with etoposide for 
24h to induce DNA damage. At the indicated time points post-treatment, total RNA was extracted, 
reverse transcribed and transcript levels of IL-6, IL-8 and IL-1b as markers for SASP were monitored by 
quantitative RT-PCR. Bars represent the mean of three technical replicates.   
 
4.1.2 Translocation and loss of MYBBP1A during DNA 
damage-induced senescence 
To address the regulation of MYBBP1A in the setting of stress-induced senescence, MYBBP1A 
protein levels were investigated following treatment. Interestingly, etoposide-treated FaDu cells 
showed a gradual decrease in MYBBP1A protein expression, while p21
CDKN1A
 as a marker of 
early cellular senescence was strongly induced (Fig. 4.4A). Co-immunofluorescence staining 
confirmed predominant localization of MYBBP1A in the nucleolus of p21
CDKN1A
 negative cells, 
and its translocation into the nucleoplasm or loss in p21
CDKN1A
 positive cells in response to DNA 
damage (Fig. 4.4B). Dissociation of MYBBP1A from the nucleolus to the nucleoplasm has been 
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reported to be associated with ribosomal stress induced by DNA damaging agents (69). Taken 
together, these results demonstrated that in response to DNA damage, MYBBP1A first 
translocated from the nucleolus to the nucleoplasm and subsequently, its protein levels decreased 
in senescent cells.   
 
Figure 4.4: DNA damage-induced senescence involves the translocation and loss of MYBBP1A 
expression in FaDu cells. Cells were pre-treated with etoposide for 24h to induce DNA damage. (A) 
Western blot analysis demonstrates decreased MYBBP1A but increased of p21
CDKN1A
 protein levels after 
the indicated time points after etoposide treatment. Detection of β-Actin served as loading control for 
protein quantity and quality. (B) Representative pictures of co-immunofluorescence staining for 
MYBBP1A (left panel) and p21
CDKN1A
 at day 3 post-treatment with etoposide. Arrow indicates a cell with 
nucleolar MYBBP1A but no p21
CDKN1A
 staining, and arrowhead indicates a cell with p21
CDKN1A
 but no 
MYBBP1A staining.  
 
In order to determine whether MYBBP1A protein down-regulation is a common feature during 
genotoxic-induced senescence, its expression was further examined in the cervical cancer cell 
line HeLa following etoposide treatment. Similar to FaDu cells, etoposide treatment in HeLa 
cells induced the typical senescence alterations including an enlarged morphology, strong 
nuclear accumulation of γH2AX as well as significant increase in SA-β-gal activity (Fig. 4.5). 
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Quantitative analysis showed that 92% of cells stained positive for SA-β-gal seven days post 
treatment, indicating a severe senescent phenotype (Fig. 4.5B).  
 
Figure 4.5: Etoposide induces DNA damage and senescence in HeLa cells. Cells were pre-treated with 
etoposide for 24h to induce DNA damage. (A) 3 days post-treatment, persistent DNA damage was 
determined by immunofluorescence staining for γ-H2AX. (B) The presence of senescent cells was 
determined by SA-β-gal staining at the indicated time points. Data are represented as percentage total of 
β-gal positive cells ± SD (n=3). Statistical analysis was performed using unpaired two tailed Student’s t-
test; *** p˂0.001. White scale bar represents 50 μm. 
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Consistent with the observations in FaDu cells, a gradual decrease in MYBBP1A protein levels 
was observed following treatment (Fig. 4.6A). Moreover, immunofluorescence studies 
confirmed the translocation and loss of MYBBP1A in senescent HeLa cells (Fig. 4.6B).   
 
Figure 4.6: DNA damage-induced senescence involves the translocation and loss of MYBBP1A 
protein in HeLa cells. Following 24hours treatment with DNA damaging agent (10 µM etoposide), 
MYBBP1A expression was analyzed. Western blot (A) and immunofluorescence staining (B) revealed 
MYBBP1A translocation and loss of protein following treatment. Detection of β-Actin served as loading 
control for protein quantity and quality. Nuclear staining with Hoechst 33324. White scale bar represents 
50 μm. 
 
4.1.3 Silencing of MYBBP1A is not sufficient to induce 
senescence in vitro 
In the past, it was proposed that down-regulation of Mybbp1a in mouse embryonic fibroblasts 
reveals a rapid entry into senescence (75). To investigate whether loss of MYBBP1A is 
sufficient to induce senescence in tumor cells, gene silencing was conducted by transient 
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transfection of FaDu cells with control (scramble) or MYBBP1A-specific siRNAs 
(siMYBBP1A). Silencing efficiency was confirmed three days post-transfection by Western blot 
analysis (Fig. 4.7A). Previously, several studies demonstrated that deletion or down-regulation of 
MYBBP1A has a profound effect on the cellular growth rate by affecting the expression of 
several genes involved in cell cycle control, DNA damage and cell death (75, 83). Consistent 
with this reports, MYBBP1A-depleted FaDu cells displayed a slight but significant decrease in 
BrdU incorporation as compared to the scramble-controls (36% v. 42%, Fig. 4.7B). However, 
silencing of MYBBP1A did not induce any marker of senescence tested, including cell or 
nuclear morphology (data not shown), p21
CDKN1A
 expression (Fig. 4.7A) and SA-β-gal staining 
(Fig. 4.7C), indicating that loss of MYBBP1A expression is not sufficient to trigger senescence 
in FaDu cells.  
 
 
Figure 4.7: Silencing of MYBBP1A is not sufficient to induce senescence in FaDu cells. (A) Efficient 
silencing of MYBBP1A 72 hours after transient transfection was demonstrated with whole cell lysate of 
FaDu-siMYBBP1A and FaDu-scramble cells by Western blot analysis. The extracts were also 
immunoblotted for the senescence marker p21
CDKN1A and detection of β-Actin was used as loading 
control. (B) Samples were analyzed for BrdU incorporation 3 days post-transfection. Data are represented 
as mean ± SD (n=6) (unpaired ratio two-tailed t-test; ** p<0.01). (c) Representative pictures of SA-β-gal 
staining (blue staining) at day 5 post transfection. White scale bar represents 50 μm. 
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4.1.4 Silencing of MYBBP1A accelerates DNA damage-induced 
senescence  
To determine whether MYBBP1A modulates the efficacy of DNA damage-induced senescence, 
FaDu cells were first transfected with control or MYBBP1A-specific siRNAs and subsequently 
subjected to etoposide. Although silencing of MYBBP1A had no major impact on basal or 
etoposide-induced p21
CDKN1A
 expression (Fig. 4.8A), it resulted in a slight but significantly 
decreased amount of BrdU positive cells after etoposide treatment (Fig. 4.8B). MYBBP1A 
depleted cells exhibited a significant increase in the relative number of senescent tumor cells at 
day 5 post-treatment (2-3 fold) as determined by SA-β-gal-positive staining (Fig. 4.8C). This 
result suggests that, in the context of DNA damage-induced senescence, inactivation of 
MYBBP1A plays a critical role in modulating the efficacy of the senescence program.  
  
Similar results were obtained upon analysis of HeLa cells with MYBBP1A silencing after 
etoposide treatment as compared to scramble-controls. Although p21
CDKN1A
 expression was 
induced by etoposide, it maintained at the same level independent of silencing of MYBBP1A 
expression (Fig. 4.9A). In addition, active replication measured by BrdU incorporation revealed 
a significant decrease in the percentage of BrdU positive cells in the MYBBP1A-delpleted cells 
compared to scramble-controls following treatment (Fig. 4.9B). After 5 days of treatment, SA-β-
gal activity was evaluated and found to be enhanced in MYBBP1A depleted cells, consistent 
with the previous results (Fig. 4.9C). Taken together, these data confirmed that loss of 
MYBBP1A is not sufficient to trigger senescence in tumor cells, but modulates the efficacy of 
genotoxic-induced senescence. 
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Figure 4.8: Silencing of MYBBP1A accelerates DNA damage-induced senescence. FaDu cells were 
transiently transfected with scramble or siRNAs directed against MYBBP1A. After 48 hours of 
transfection, cells were incubated in the presence or absence of 10 µM etoposide for 24 hours and 
subsequently cultured for 5days. (A) Cell lysates were subjected to Western blot analysis for indicated 
proteins 5 days post-treatment. β-Actin served as a loading control. (B) Samples were analyzed for BrdU 
incorporation 5 days post-etoposide treatment. Data are represented as percentage total of cells ± SD 
(n=6) (unpaired ratio two-tailed t-test; * p<0.05). (C) Samples were fixed and analyzed for SA-β-gal 
activity 5 days post treatment. Quantification of SA-β-Gal-positive cells revealed increased relative 
amounts of positive cells for siMYBBP1A transfected cells as compared to scramble controls. Data are 
expressed as percentage total of cells ± SD (n=3) (unpaired ratio two-tailed t-test; *** p<0.001). White 
scale bar represents 50 μm.   
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Figure 4.9: Silencing of MYBBP1A expression accelerates DNA damage-induced senescence in 
HeLa cells. HeLa cells were transiently transfected with scramble and siMYBBP1A. At day 2, 
transfected cells were treated with 10 µM etoposide for 24 hours. (A) Cell lysates were subjected to 
Western blot analysis for indicated proteins 5 days post-treatment. Detection of β-Actin served as loading 
control for protein quantity and quality. (B) Samples were analyzed for BrdU incorporation 5d post-
treatment. Data are represented as mean ± SD (n=3) (unpaired ratio two-tailed t-test; * p≤0.05). (C) 
Samples were fixed and analyzed for SA-β-Gal activity 5d post-treatment. Data are represented as 
percentage total of cells ± SD (n=3) (unpaired ratio two-tailed t-test; ** p˂0.01). White scale bar 
represents 50 μm. 
 
4.1.5 Ectopic overexpression of MYBBP1A attenuates DNA 
damage-induced senescence 
To dissect the functional role of MYBBP1A in cellular senescence, HeLa cells were transiently 
transfected with control (Mock) or FLAG-tagged amino-terminal region of MYBBP1A 
(MYBBP1A
p67
) and subjected to etoposide treatment. Unlike the full length MYBBP1A (also 
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known as p160), its shorter N-terminal 67 kDa fragment has been shown to be more stable (72). 
Western blot analysis with Anti-FLAG antibodies reveled prominent ectopic protein expression, 
which was also detectable after etoposide treatment (Fig. 4.10A). Furthermore, the expression of 
markers of senescence and proliferation was analyzed in these cells. Despite the expression of 
MYBBP1A, no difference was observed in γH2AX staining and p21CDKN1A induction post 
treatment (Fig. 4.10B). Although no obvious difference in early markers of senescence was 
found, MYBBP1A
p67
 cells displayed increased BrdU incorporation (Fig. 4.10C) and decreased 
SA-β-gal activity as compared to control after treatment (Fig. 4.11). These results demonstrate 
that overexpression of MYBBP1A could bypass genotoxic-induced senescence. 
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Figure 4.10: Ectopic overexpression of MYBBP1A
p67
 in HeLa cells. HeLa cells were transiently 
transfected with control (mock) and a MYBBP1A
p67
 expression plasmid. At day 2, transfected cells were 
treated with 10 µM etoposide for 24 hours. (A) Cell lysates were subjected to Western blot analysis for 
indicated proteins 5 days post-treatment. Detection of β-Actin served as loading control for protein 
quantity and quality. (B) 5 days post-treatment, persistent DNA damage was determined by 
immunofluorescence staining for γ-H2AX (green fluorescence). (C) Samples were analyzed for BrdU 
incorporation (red fluorescence) 5 d post-treatment. Nuclear staining with Hoechst 33324. White scale bar 
represents 50 μm.  
 
 
Figure 4.11: Ectopic overexpression MYBBP1A
p67
 attenuates DNA damage-induced senescence in 
HeLa cells. HeLa cells were transiently transfected with Mock and MYBBP1A
p67
. At day 2, transfected 
cells were treated with 10 µM etoposide for 24 hours. (A) Samples were fixed and analyzed for SA-β-Gal 
activity 5d post-treatment. (B) Quantification of SA-β-Gal-positive cells revealed decreased relative 
amounts of positive cells for MYBBP1A
p67
 transfected cells as compared to Mock controls. Data are 
expressed as percentage total of cells ± SD (n=3). Nuclear staining with Hoechst 33324. White scale bar 
represents 50 μm.   
 
4.1.6 Knockdown of MYBBP1A expression modulates the 
expression of SASP factors and confers radio-resistance 
MYBBP1A was demonstrated as an important repressor of NFκB-dependent transcription (78), 
and in response to DNA damage activated NFκB conferred induction of SASP (141). 
Consequently, MYBBP1A-dependent alterations in the transcription of SASP related cytokines 
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were analyzed in DNA damage-induced senescent cells. Upon etoposide treatment FaDu-
siMYBBP1A cells exhibited slightly increased expression of IL-6, IL-1β and TGF-β as 
compared to scramble controls, which did not reach statistical significance (Fig. 4.12). These 
results support the assumption that MYBBP1A might represent a key player towards 
maintenance rather than the initiation of senescence.  
 
Figure 4.12: Silencing of MYBBP1A accelerates expression of SASP components following DNA 
damage. FaDu-Mock and FaDu-siMYBBP1A cells were treated in the presence (+) or absence (-) of 
etoposide for 24h after transient transfection. At day 5 post-treatment total RNA was extracted for 
quantitative RT-PCR. Relative transcript levels of the SASP-related cytokines IL-1β, IL-8, IL-6 and TGF-
β are given as mean value ± SD (n=3). Unpaired ratio two-tailed t-test; n.s. = not significant. 
 
Results so far indicated that silencing of MYBBP1A accelerates the DNA damage-induced 
senescence and modulates the expression of SASP components. Next, the impact of MYBBP1A 
silencing on the sensitivity of FaDu cells to irradiation was determined. FaDu cells were 
transfected with MYBBP1A specific siRNA or scramble controls and 48h post-transfection cells 
were exposed to a single dose of 5 Gy. Radiosensitivity was determined by a colony-forming 
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assay (CFA) and revealed an almost 2-fold increase in clonogenic survival for siMYBBP1A 
transfected cells as compared to the scramble controls (Fig. 4.13). To our knowledge, these result 
shows for the first time that loss of MYBBP1A expression is associated with radio-resistance.   
 
 
Figure 4.13: Knockdown of MYBBP1A expression confers radioresistance. FaDu cells were 
transiently transfected with control and MYBBP1A specific siRNAs. 48h post-transfection, cells were 
irradiated with a single dose (5 Gy). Following treatment, cells were cultured for 10 days and colonies 
were stained with crystal violet. (A) Representative images demonstrate increased numbers of colonies 
for MYBBP1A depleted cells after irradiation compared with scramble controls. (B) Results are 
represented as the mean surviving fraction (± SD), which was determined for three independent 
experiments (unpaired ratio two-tailed t-test; * p<0.05).    
 
4.2 MYBBP1A-PI3K/AKT signaling cascade in stress-
induced senescence in vitro 
Protein kinase B is the major effector of the phosphoinositide 3-kinase (PI3K) pro-survival 
pathway (142). In the context, activation of the PI3K/AKT pathway (Fig. 1.4) was regarded as an 
essential survival signal to counteract the pro-apoptotic effects under stress conditions or 
presence of DNA damaging agents, which might also promote tumorogenesis (143, 144). 
Accordingly, PI3K/AKT pathway activation might act as a pivotal survival signal during DNA 
damage-induced senescence.  
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4.2.1 Activation of the PI3K/AKT pathway in stress-induced 
senescence 
To investigate activation of PI3K/AKT pathway as a function of DNA damage-induced 
senescence, phosphorylation of AKT on Ser473 was analyzed in FaDu and HeLa cells following 
etoposide treatment. As shown in Fig. 4.14A, FaDu cells showed loss of MYBBP1A expression 
and a strong increase in AKT phosphorylation (pAKT(Ser473)) in response to etoposide by 
Western blot analysis, which was consistent with previous observations (143, 145). Similar data 
concerning inverse regulation of MYBBP1A protein and pAKT(Ser473) were also detected in 
HeLa cells after etoposide treatment (Fig. 4.14B). It is worth noting that the response kinetics 
was heterogeneous and slightly different in FaDu and HeLa cells. Collectively, these data 
strongly suggest that low MYBBP1A expression and parallel rise in pAKT(Ser473)
 
may indicate 
tumor cells in a pre-senescent stage.  
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Figure 4.14: Inverse regulation of MYBBP1A and pAKT(Ser473) protein levels after DNA damage. 
(A) Inverse regulation of MYBBP1A and pAKT(Ser473) protein levels were determined by Western blot 
analysis with whole cell lysate of control (0 day) and etoposide-treated FaDu cells. Detection of total 
AKT and β-Actin served as a loading control for protein quality and quantity. Signals were quantified by 
ImageJ and bar graphs show changes in MYBBP1A/β-Actin and pAKT(Ser473)/AKT ratios normalized 
to control at day 0 are shown beside the blots. Data represent mean ± SD of three independent 
experiments. (B) Western blot analysis and quantification of MYBBP1A and pAKT(Ser473) protein 
levels post treatment in HeLa cells.  
 
4.2.2 Loss of MYBBP1A during DNA damage induced 
senescence is independent of AKT signaling 
To investigate whether the activation of AKT signaling is causally linked to loss of MYBBP1A 
expression, level of pAKT(Ser473) was analyzed in FaDu and HeLa cells following silencing of 
MYBBP1A expression. Similar to previous result, efficient silencing of MYBBP1A was 
observed 72h after transfection in both cell lines. However, no difference in pAKT(Ser473) 
levels were seen between cells transfected with either control or MYBBP1A-specific siRNA 
(Fig. 4.15), suggesting that activation of AKT signaling is not related to the loss of MYBBP1A 
expression.    
               
Figure 4.15: Loss of MYBBP1A expression does not induce AKT phosphorylation. (A) Efficient 
silencing of MYBBP1A 72 hours after transient transfection was demonstrated with whole cell lysate of 
FaDu and HeLa cells by Western blot analysis. The extracts were also immunoblotted for pAKT(Ser473). 
 
Detection of total AKT and β-Actin served as a loading control for protein quality and quantity. 
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To further address the question whether genotoxic-induced down-regulation of MYBBP1A is 
under the influence of activation of PI3K/AKT pathway, FaDu cells were treated with etoposide 
in the presence or absence of potent inhibitors. LY294002 (20 μM) was used to inhibit PI3K and 
Triciribine (20 μM) to inhibit AKT, the downstream effector of PI3K (Fig. 4.16). However, 
inhibition of AKT had no major impact on MYBBP1A protein levels upon etoposide treatment. 
In contrast to a previous report (143), LY294002 treatment did not provoke inhibition of AKT 
phosphorylation as detected by Western blot analysis. Interestingly, LY294002 stabilizes the 
expression of MYBBP1A post treatment. These results suggest that, although inhibition of PI3K 
mediated stabilization of MYBBP1A protein post etoposide treatment, AKT was not essential to 
transduce the signal and may potentially be regulated via other pathways.    
                               
Figure 4.16: Increased MYBBP1A protein stability by LY294002 treatment in the presence of 
genotoxic stimuli. Cells were treated with (+) or without (-) etoposide (10 μM), LY294002 (20 μM) or 
Triciribine (10 μM) as indicated. After 72h the cells were lysed and the expression of MYBBP1A and 
pAKT(Ser473) was determined by Western blot. Detection of total AKT and β-Actin served as a loading 
control for protein quality and quantity. 
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4.2.3 Post transcriptional modifications for MYBBP1A protein 
stability 
In the past, it has been suggested that MYBBP1A protein stability was regulated by post-
transcriptional modifications, including ubiquitination and proteasomal degradation (71). 
Accordingly, MYBBP1A transcript and protein levels were analyzed in a panel of HNSCC cell 
lines and HeLa cells. Accordingly, SCC-25 cell line showed comparable transcript levels with 
Cal-27, but difference in the protein levels (Fig. 4.17A-B). However, FaDu and HeLa cell lines 
showed prominent expression at the transcript and protein level. This finding suggested a post-
translational mechanism for the regulation of MYBBP1A protein levels. In line with this 
assumption, preliminary data demonstrated that treatment of SCC-25 cells that exhibit 
MYBBP1A transcripts but only low protein levels with the proteasome inhibitor MG-132 
resulted in increased protein stability when compared to untreated controls (Fig. 4.17C). To 
further investigate the regulation of MYBBP1A protein stability by ubiquitination during DNA 
damage-induced senescence, SCC-25 cells were pre-treated with MG-132 followed by 
incubation with etoposide. As depicted in Fig. 4.17D, cells did not survive following MG-132 
treatment in the presence of etoposide, mostly due to strong induction of apoptosis (146). Even 
though, MYBBP1A protein levels are at least in part regulated by posttranslational 
modifications, the molecular mechanism resulting in the loss of MYBBP1A expression in the 
presence of genotoxic stimuli remains elusive and will be a major challenge for the future.  
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Figure 4.17: MYBBP1A protein stability by ubiquitination and toxicity of MG-132 in the presence 
of genotoxic stimuli. MYBBP1A expression in a panel of HNSCC cell lines and HeLa cells was 
determined at protein level by Western immunoblot (A), while transcript levels were analyzed by 
quantitative RT-PCR (B). (C) Western blot analysis demonstrates stabilization of MYBBP1A protein 
after the indicated time of MG-132 (10 μM) treatment in SCC-25 cells. β-Actin served as a loading 
control. (D) Microscopic analysis revealed dramatic decrease in the cell survival following treatment of 
FaDu cells with MG-132 (10 μM) and etoposide (10 μM).     
 
4.2.4 SCC-25 an in vitro model for post-senescent tumor cells 
As loss of MYBBP1A expression was associated with DNA damage-induced senescence, the 
presence of additional markers for senescence was investigated in parental SCC-25 cells. In line 
with a previous publication (53), SCC-25 cells exhibited high pAKT(Ser473) levels. In addition, 
SCC-25 cells under normal culture conditions were characterized by enlarged cell morphology, 
increased p21
CDKN1A
 expression and nuclear γH2AX staining as compared with other HNSCC 
cell lines (Fig. 4.18A-B). Quantitative RT-PCR also demonstrated increased transcript levels of 
SASP-related cytokine IL-1β in SCC-25 cells (Fig. 4.18C). Even though, SCC-25 showed 
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several features of senescence, SA-β-gal activity was not detectable (Fig. 4.19A), suggesting that 
these cells might represent a post-senescent cells that regained the capacity to proliferate.           
 
Figure 4.18: SCC-25 an in vitro model for post-senescent tumor cells. (A) In a panel of HNSCC cell 
lines, the levels of MYBBP1A, pAKT(Ser473) and the senescence marker p21
CDNK1A
 were investigated 
by Western blotting. β-Actin served as a loading control. (B) SCC-25 cells were cultured, fixed and 
analyzed by immunofluorescence with the γ-H2AX antibody. Nuclear staining with Hoechst 33324. 
White scale bar represents 50 μm. (C) Total RNA was extracted; reverse transcribed and transcript level 
of IL-1β was monitored by quantitative RT-PCR in a panel of HNSCC cell lines. Bars represent mean 
value of three technical replicates. 
 
To further characterize the DNA damage-induced senescence phenotype, SA-β-gal activity was 
determined in SCC-25 cells following etoposide treatment. Interestingly, no obvious increase in 
SA-β-gal activity was found in SCC-25 cells at day 5 post-treatment, while most FaDu cells that 
served as positive control were SA-β-gal positive (Fig. 4.19B). Taken together, these results 
suggest that SCC-25 represents a bona fide in vitro model for post-senescence with 
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MYBBP1A
low
pAKT
high
 expression and some features of senescence except SA-β-gal activity. 
Moreover, SCC-25 showed treatment resistance towards genotoxic stimuli.  
        
Figure 4.19: Response of SCC-25 cells towards exposure to etoposide. FaDu and SCC-25 cells were 
assessed for SA-β-gal activity in the presence (B) and absence (A) of etoposide. Hoechst staining was 
used to visualize DNA. White scale bar represents 50 μm. 
    
4.3 Clinical relevance of senescent tumors cells in 
OPSCC patients 
Even though senescence is often described in the context of therapeutic benefits in HNSCC (147, 
148), our knowledge concerning its correlation with clinical and histopathological characteristics 
as well as the clinic outcome remains limited. In the past, several clinical and experimental 
studies demonstrated a paracrine cross talk between senescent cells and adjacent tumor cells 
during malignant progression and conditions of treatment failure (108, 149). To gain further 
insight into the clinical relevance of our findings, protein levels of MYBBP1A, total AKT and 
pAKT(Ser473) were analyzed in tissue samples from human primary OPSCC patients (n=61) 
(Fig. 4.20).   
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Figure 4.20: Heterogeneous pattern of MYBBP1A and pAKT(S473) protein levels in primary 
tumors of OPSCC patients. (A) Representative images of immunohistochemical (IHC) staining for low 
(left panel) and high expression (right panel) of MYBBP1A, pAKT(S473) and AKT on tissue sections of 
primary OPSCCs (brown signal). Counterstaining was performed with Hematoxyline.  
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4.3.1 Correlation analysis of MYBBP1A
low
pAKT
high
 expression 
score with clinical and histopathological features 
The relative amount of positively stained cells and the staining intensity for MYBBP1A, pAKT 
and AKT proteins were determined by three independent observers (Kindly provided by Gustavo 
A Sanhueza and Dominik Horn). A combinatorial analysis revealed a subgroup of seven patients 
with MYBBP1A
low
pAKT(Ser473)
high
 staining pattern relative to combination of all other 
patterns (n=54). Subsequently, the expression pattern was compared with several clinico-
pathological patient parameters (Table 4.1). Patients with an age group˂58, current alcohol and 
tobacco consumption, HPV non-driven tumors, large tumor size, lymph node metastasis, and 
advanced clinical stages tended to show a MYBBP1A
low
pAKT(Ser473)
high 
staining pattern, but 
the associations were not statistically significant. Moreover, two patients with distant metastasis 
showed a significant correlation with in the primary tumor (p=0.012), but the relevance of this 
finding was hampered by the small amount of patients with distant metastasis in our study 
cohort. In summary, the MYBBP1A
low
pAKT(Ser473)
high 
staining pattern confirmed the presence 
of pre-senescent or senescent tumor cells in a subpopulation of OPSCC patients, which was not 
significantly correlation with any clinico-pathological feature tested.   
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4.3.2 MYBBP1A
low
pAKT(Ser473)
high 
staining pattern in 
primary tumors of OPSCC patients confers a poor 
prognosis 
Next, the possibility was analyzed whether MYBBP1A
low
pAKT(Ser473)
high 
expression could 
serve as a prognostic biomarker for OPSCC patients. The MYBBP1A
low
pAKT(Ser473)
high 
expression score was compared with progression free survival (PFS) as well as overall survival 
(OS). Univariate Kaplan-Meier analysis revealed a significantly higher probability for patients 
with a MYBBP1A
low
pAKT(Ser473)
high 
staining pattern to have shorter PFS (p=0.007) (Fig. 
4.21A). Moreover, a significant correlation was found between the 
MYBBP1A
low
pAKT(Ser473)
high
 expression score and a poor OS (p<0.001) as compared to 
patients with all other combination scores. In summary, this data suggested an inverse regulation 
of MYBBP1A and pAKT(Ser473) protein levels in the pathogenesis of OPSCC and that patients 
with MYBBP1A
low
pAKT(Ser473)
high 
expression are at high risk for unfavorable clinical 
outcome.        
4.3.3 MYBBP1A
low
pAKT(Thr308)
high 
staining pattern was not 
associated with poor prognosis in OPSCC patients  
It is worth mentioning that full activation of AKT requires phosphorylation at Thr308 and 
Ser473 by PDK1 and mTORC2, respectively (48). Therefore, primary OPSCC tumor samples 
were analyzed for pAKT Thr308 expression and scored as described above.  PFS was calculated 
according to the stratification of patients with MYBBP1A
low
pAKT(Thr308)
high
 staining (n=7) 
and all other combination patterns (n=47). No significant impact on patient outcome was 
observed (Fig. 4.22A). Also, the presence of MYBBP1A
low
pAKT(Thr308)
high 
tumor cells within 
the tumor mass did not influence overall survival (Fig. 4.22B). Remarkably, significant 
correlations were only found considering AKT phosphorylation at Ser473 but not at Thr308, 
suggesting a more critical role of mTOR/AKT signaling for the clinical behavior of OPSCC 
patients with low MYBBP1A expression.  
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Figure 4.21: Inverse MYBBP1A expression and AKT (Ser473) phosphorylation is associated with 
unfavorable clinical outcome. Kaplan-Meier plot for progression-free (A) and overall survival (B) 
revealed that patients with low MYBBP1A expression but high levels of pAKT(Ser473) had a 
significantly reduced survival as compared to others. 
 
  
Figure 4.22: MYBBP1A
low
pAKT(Thr308)
high
 does not serve as unfavorable risk factor in primary 
OPSCC patients. Kaplan-Meier plot for progression-free (A) and overall survival (B) according to low 
or high MYBBP1A and pAKT(Thr308) protein levels in primary tumors of OPSCC patients revealed no 
significant correlation with survival. 
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4.3.4 MYBBP1A
low
pAKT(Ser473)
high 
staining pattern served as 
an independent risk factor for unfavorable clinical 
outcome of OPSCC patients  
Prognostic significance was further evaluated by a multivariate Cox proportional hazard analysis 
(Table 4.2). Multivariate Cox regression including putative prognostic factors and the HPV 
status revealed a statistically significant association only for MYBBP1A
low
pAKT(Ser473)
high
 
with a higher risk for OPSCC related death (HR=7.10; 95% CI=1.85-27.24; p=0.03). These 
results demonstrated that a MYBBP1A
low
pAKT
high 
staining pattern served as an independent risk 
factor for unfavorable clinical outcome of OPSCC patients.  
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5 Discussion 
5.1 Loss of MYBBP1A expression is a common feature 
during DNA damage-induced senescence 
MYBBP1A has been implicated in distinct biological functions such as cell proliferation, DNA 
damage and cell death. As such, research efforts have been focused on understanding the critical 
role of MYBBP1A in adult tissue function or homeostasis. However, the physiological function 
of MYBBP1A during senescence and the detailed mechanisms underlying these activities have 
yet to be elucidated. The goal and the scope of the present study were to identify the novel 
function of MYBBP1A in DNA damage-induced senescence.    
Topoisomerase inhibitors such as etoposide are commonly used in anti-neoplastic therapy to 
induce DNA damage in tumor cells and to limit the propagation of damaged and stressed cells by 
cell cycle arrest or apoptosis (150, 151). It has also been shown that etoposide is able to induce 
senescence in normal human fibroblast, colon, ovarian and adenocarcinoma cell lines (136, 139). 
In line with this, the two human carcinoma cell lines FaDu and HeLa, which were used in this 
study, respond to etoposide by inducing cellular senescence. Our data are consistent with a 
model in which genotoxic DNA damage induces the activation of p21, which may sustain G2/M 
phase arrest as well as the formation of abnormally shaped giant cell and nuclei (139). In 
response to DNA damage, MYBBP1A first translocated from the nucleolus to the nucleoplasm 
and subsequently, its protein levels decreased in senescent cells (Fig. 5.1). This finding is in line 
with the studies by Kuroda et al. (69) and Yamauchi et al. (71), showing that stress signals which 
inhibit ribosomal biosynthesis induce nuclear disruption and lead to translocation of the 
nucleolar protein MYBBP1A into the nucleoplasm. However, this is the first study 
demonstrating that loss of MYBBP1A protein in the establishment of a senescent phenotype.   
                                                                           77                                                                   DISCUSSION                           
  
It is widely accepted that the p53 tumor suppressor protein is pivotal for the initiation and 
maintenance of senescence growth arrest (91, 152), mainly following its activation by the DNA 
damage response via ATM-mediated phosphorylation. Moreover, activated p53 triggers the 
expression of pro-senescence target genes such as p21, affecting several physiological and 
metabolic pathways responsible for the establishment of senescence (153). Interestingly it has 
been shown that MYBBP1A regulates p53 function by acetylation to induce cell cycle arrest and 
apoptosis (69). Several studies have shed light into this issue and have proven that under 
nucleolar stress MYBBP1A specifically interacts with nonacetylated lysine residues of p53 and 
induces its acetylation, which enables the effective p53-activating function (69, 79, 80). The fact 
that both FaDu and HeLa cell lines used in this study express no or only mutated p53 suggest 
that the regulation of MYBBP1A as well as its putative mode of action in senescence may be in a 
p53-independent manner. However, at the current state it cannot be ruled out that mutant p53 can 
also drive a senescence response to DNA damage (154). For example, a single mutation in p53, 
E177R, abolishes the apoptotic function of p53 while retaining control of cell cycle and 
senescence functions (155). Further investigation will be required to clarify this issue.  
5.2 Silencing of MYBBP1A modulates the efficacy of 
genotoxic-induced senescence 
A growing body of evidence indicates that deletion or down-regulation of MYBBP1A has a 
profound effect on the growth rate of cells by affecting the expression of several genes involved 
in cell cycle control, DNA damage and cell death (75, 83). Down-regulation of MYBBP1A was 
also reported to be involved in the transcriptional induction of p21
CDKN1A
 by a p53-independent 
mechanism (75). Evidently, primary mouse embryonic fibroblast (MEFs) from MYBBP1A 
knockout mice showed a rapid entry into senescence (75). Therefore, the effect of MYBBP1A 
silencing on senescence was investigated in tumor cells. Although, a significant decrease in the 
number of BrdU positive cells was observed following MYBBP1A depletion, it has no direct 
effect on the induction of senescence markers such as p21
CDKN1A
 and SA-β-gal staining tested.  
However, silencing of MYBBP1A under stress conditions resulted in an increase in the relative 
amount of SA-β-gal positive cells as well as SASP factors, although the expression of p21CDKN1A 
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did not change. Based on these observations, it was tempting to hypothesize that translocation 
and further loss of MYBBP1A expression following DNA damage are not necessary to trigger 
the senescence program but modulates its efficacy.   
MYBBP1A was demonstrated as an important repressor of NFκB dependent transcription, by 
competing with the co-activator p300 for interaction with RelA/p65 (78). Several publications 
also pointed to the nuclear accumulation of p65 upon etoposide treatment accompanied by the 
stimulation of serine-536 phosphorylation, indicating transcriptionally active RelA/NFκB (156-
158). Indeed, we observed pRelA/p65 nuclear staining in tissue sections of primary OPSCC 
patients with low MYBBP1A protein expression (data not shown). In response to DNA damage 
NFκB activation conferred induction of SASP by influencing the expression of NFκB target 
genes (141, 159, 160). Similar results have been reported in which NFκB inhibition by either 
genetic depletion or a pharmacological inhibitor attenuates SASP and delays DNA damage-
induced senescence (161, 162). However, we cannot rule out the possibility that the observed 
increase in SASP in FaDu cells with silenced MYBBP1A expression reflects the relative 
abundance of senescent cells post treatment rather than a direct influence on NFκB activity.  
To demonstrate a causal link between MYBBP1A ablation and DNA damage-induced 
senescence, we aimed to revert the senescent phenotype by ectopic overexpression of a stable 
amino-terminal variant of MYBBP1A (p67) in HeLa cells. Compared to the full-length 
MYBBP1A protein (p160), p67 lacks the C-terminal region containing the nucleolar localization 
sequence (68). Interestingly, it has been shown that the nucleolar full-length protein stimulates 
ribosome biogenesis and that the translocation of MYBBP1A from the nucleolus to the 
nucleoplasm upon ribosome stress plays an important role to block cell cycle progression by 
suppressing c-Myb target genes (71). Furthermore, an increasing number of studies report the 
important role of the nucleolus in cell cycle regulation and senescence (163, 164). Accordingly, 
expression analysis of markers of senescence and proliferation following etoposide treatment 
revealed severely diminished SA-β-gal activity and increased proliferation in the HeLa-
MYBBP1A (p67)
 cells, while nuclear γH2AX staining and p21 induction were unaltered 
compared to mock controls. These results strongly suggest that in response to stress signals, 
translocation and abrogation of MYBBP1A plays an important role in cellular senescence.   
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Figure 5.1: Schematic model for the critical role of MYBBP1A in the establishment of senescence 
induced by DNA damage. Proposed model for the regulation and function of MYBBP1A in DNA 
damage-induced senescence. In response to DNA damage, MYBBP1A first translocates from the 
nucleolus to the nucleoplasm. Loss of MYBBP1A expression was not sufficient to trigger senescence, but 
modulates the efficacy of a genotoxic-induced senescence. Relative abundance of senescent cells could 
also contribute to accelerate the availability of SASP factors. 
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5.3 Inverse regulation of MYBBP1A and AKT 
phosphorylation resembles a senescent like phenotype 
The RAS-PI3K-AKT signaling pathway is one of the major mediators of cellular 
survival/apoptosis determinant. In the context of persistent DNA damage, sustained activation of 
the AKT pathway alleviates cellular stress and ultimately, promotes cellular survival by 
mechanisms involving the regulation of anti-apoptotic proteins such as Bcl-2 and Bcl-xl (144, 
165). Multiple lines of evidence also indicate that constitutive activation of PI3K/AKT signaling 
leads to the accumulation of reactive oxygen species followed by an irreversible proliferation 
arrest (senescence) via a p53/p21-dependent pathway (166, 167). Moreover, activation of this 
pathway through PTEN loss, overexpression or activating mutation of PI3K (PI3KCA) and 
overexpression of AKT can trigger oncogene-induced senescence (OIS) in primary murine 
fibroblasts and multiple lines of cultured endothelial cells (88, 114, 167, 168). Together, these 
emerging evidences point to a pivotal role of PI3K/AKT signaling cascade during DNA damage-
induced senescence. In line with these findings, our data showed that etoposide treatment 
induces the phosphorylation of AKT along with the loss of MYBBP1A expression.  
In light of increasing evidence that posttranslational mechanisms, including ubiquitination and 
proteasomal degradation, regulate MYBBP1A protein stability by a not yet fully understood 
molecular mechanism (66, 71), it is tempting to speculate that activation AKT might encounter a 
critical function for MYBBP1A. To examine the role of AKT activation on the down-regulation 
of MYBBP1A protein levels, FaDu cells were treated with etoposide in the presence or absence 
of Triciribine, a potent inhibitor of AKT activity (169). However, inhibition of AKT had no 
major impact on the MYBBP1A protein levels upon etoposide treatment. Conversely, no 
difference in pAKT(Ser473) levels were seen between FaDu cells transfected with either control 
or MYBBP1A-specific siRNA. In summary, these data demonstrated that loss of MYBBP1A in 
combination with increased pAKT(Ser473) levels represents a characteristic feature of genotoxic 
induced senescence of tumor cells, but questioned a direct causal link. Interestingly, inhibition of 
PI3K pathway by LY294002 after etoposide treatment stabilizes the expression of MYBBP1A 
without influencing the AKT activity. This is most likely due to the fact that LY294002 is also a 
potent inhibitor of other kinases implicated in DNA stress response, such as DNA-PK, ATM, 
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and ATR (170). The finding that, inhibition of PI3K was not sufficient to repress AKT protein 
can be explained by a possible scenario where activation of receptor signaling in cells exposed to 
this inhibitor activates PI3K as well as parallel pathways by physiologic feedback inhibition of 
the other components of the signaling network (171, 172). Accordingly, other signaling cascades 
might be responsible for the loss of MYBBP1A upon DNA damage. A recent study demonstrates 
that Tripeptidyl-peptidase II (TPPII) interacts with MYBBP1A and the cell cycle regulator 
CDK2 that is involved in the regulation of cell cycle, apoptosis and senescence (173). It is worth 
noting that MYBBP1A has been linked to mitosis and DNA damage responses, since 
MYBBP1A was identified as a novel substrate for Aurora B kinase (81) and cell-cycle 
checkpoint kinase 1 (CHK1) (174). Interestingly, MYBBP1A is phosphorylated by Aurora B 
kinase (81) and inhibition of Aurora kinases is associated with senescence (175). This suggests a 
possible functional role of Aurora B kinase or CHK1 in the regulation of MYBBP1A stability 
during genotoxic induced senescence, which needs to be addressed by functional studies in the 
future.   
OIS by aberrant activation of PI3K/AKT signaling was earlier described as a tumor-suppressing 
defense response that restricts the progression of benign lesion to malignancy in vivo (114). 
However, Damsky et al. (176) demonstrated that instead of mediating senescence, activation of 
the PI3K/AKT pathway abrogates senescence induction by BRAF
V600E 
and allows resumption of 
proliferation. Mouse models have shown that Cdkn2a loss primes a subset of growth-arrested 
Braf
V600E
 nevi is involved in melanoma development, and along with PI3K/mTOR/AKT 
activation, may encourage tumorogenesis (113, 177, 178). These observations are in agreement 
with another study, which has also shown that Pten inactivation and PI3K activation in senescent 
nevi can rapidly induce murine cancers (179). In this respect, the cell culture experiments of the 
present work would suggest that under conditions of DNA damage, activation of AKT signaling 
is critical in mediating the bypass of senescence, leading to the question of whether our results 
represent a pre-senescence or post-senescence phenotype. The assumption that the activation of 
PI3K pathway represents a post-senescent phenotype that regains the capacity to proliferate is 
further underscored by findings on the senescence features in SCC-25 cells. Even though, under 
normal condition SCC-25 showed several features of senescence in addition to 
MYBBP1A
low
pAKT
high 
protein levels, SA-β-gal activity was not detectable. To this point, next-
generation sequencing (NGS) analysis of HNSCC cell lines revealed TP53, CDKN2A and 
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PIK3CA mutations in SCC-25 (180). This observation is in accordance with prior work 
suggesting that activation of the PI3K/AKT pathway due to Pten deletion and loss of TGF-β 
signaling pathway in HNSCC cell lines, results in cancer progression through cellular senescence 
evasion (53). It is worth noting that the PTEN/PI3K/AKT pathway is the most frequently altered 
signaling node in head and neck cancer and have critical roles in driving tumor growth and 
proliferation (53, 181). Together, these results suggest that SCC-25 represent a bona fide in vitro 
model for post-senescence, where loss of MYBBP1A and PI3K/AKT activation results in 
bypassing senescence and resumes cancer progression, presumably in the setting of additional 
stochastic events. Nonetheless, these findings have implications for the molecular pathogenesis 
of precursor to cancer progression with regard to senescence, a topic with significance for 
therapy.  
5.4 MYBBP1AlowpAKT(Ser473)high staining pattern serves 
as a promising biomarker for OPSCC patients at high 
risk for treatment failure  
The in vitro experiments demonstrate a causal link between loss of MYBBP1A and the 
establishment of a senescent phenotype after etoposide treatment. Moreover, the data clearly 
shows that an inverse regulation of MYBBP1A and AKT phosphorylation on Ser473 is a 
characteristic feature of senescent tumor cells. To gain further insight into the clinical relevance 
of these findings, MYBBP1A expression and AKT phosphorylation patterns were investigated 
on tumor sections of primary OPSCC. The staining pattern was compared with clinical and 
histopathological features, but revealed no significant correlation except for distant metastasis. 
The relevance of this finding was hampered by the small number of patients in the cohort with 
distant metastasis. Additional retrospective and prospective studies using tumor samples of larger 
patient cohorts will be needed to support the association between 
MYBBP1A
low
pAKT(Ser473)
high 
staining and clinical as well as pathological features.  
Considering that Akt activation is a significant prognostic indicator for oral squamous cell 
carcinoma (182, 183), it is also conceivable to postulate that in the clinical setting a 
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MYBBP1A
low
pAKT(S473)
high 
has a prognostic value and might stratify patients at high risk for 
treatment failure. The presented data that a MYBBP1A
low
pAKT(S473)
high 
staining pattern is 
significantly correlated with poor PFS and OS strongly supports this assumption and suggests 
that the presence of cells with a senescent-like phenotype can be used as a promising biomarker 
for OPSCC patients. Strikingly, significant correlations were only found considering AKT 
phosphorylation at S473 but not at T308, suggesting a more critical role of mTOR/AKT 
signaling for the clinical behavior of OPSCC patients with low MYBBP1A expression. In line 
with this data, the clinical benefit of targeting PDK1, the upstream kinase of AKT (Thr308) 
phosphorylation, was limited in HNSCC (184). Indeed, there are several lines of evidence 
suggesting that pAkt accumulation and PTEN down-regulation detected in HNSCC contributes 
to malignant progression from normal epithelium to dysplasia and then to infiltrating carcinoma 
(181, 182, 185). Owing to the pronounced activity of mTOR/AKT signaling in surgical margins 
of HNSCC patients, AKT activation has been found to be an independent risk factor for 
recurrence and second primary tumors (186). Likewise, the activation of downstream 
components of PI3K signaling is associated with a worse clinical outcome as shown for patients 
with lung, colon and esophageal adenocarcinomas (187-189). While, most studies assign pro-
tumorigenic and pro-metastatic function to PI3K/AKT/mTOR pathway by regulating cell 
growth, survival, angiogenesis and therapy resistance (190, 191), many recent studies also report 
senescence associated adverse effects (53, 167, 192).     
In summary, the presented data clearly indicates that OPSCC patients with a 
MYBBP1A
low
pAKT
high 
staining pattern have a poor clinical outcome, which might be due at 
least in part to the presence of senescent tumor cells (Fig. 5.2). In this context, it is worth noting 
that most of the patients in the retrospective cohort of OPSCC patients were treated with first-
line or adjuvant radiotherapy. Radiation exerts its anticancer effects primarily by inducing DNA 
double-strand breaks and activation of DNA damage response, subsequently resulting in therapy-
induced cellular senescence (TCS) (193). Several studies support the premise that a subset of 
tumor cells might eventually overcome senescence and regain clonogenic potential, thus drive 
the genesis of malignancy, leading to tumor recurrence (194-198). Tumor cells in a state of 
prolonged TCS will have a continuing impact on therapy outcomes because of their SASP 
activity, which may actually promote growth and progression of surviving tumor cells (199). 
Moreover, the PI3K/AKT/mTOR pathway has been implicated in therapeutic resistance and was 
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identified as a suitable drug target in HNSCC (51, 200, 201). In accordance with these reports, an 
improved clonogenic survival of MYBBP1A depleted FaDu cells after irradiation was 
demonstrated by a CFA assay, which could at least in part contribute to treatment failure of 
tumors enriched with the presence of MYBBP1A
low
pAKT
high
 tumor cells. An equal if not greater 
concern is that in several studies the emergent cells from the TCS phenotype were often 
characterized as highly malignant and/or therapy resistant tumor cells (193, 202, 203). In support 
of this assumption, SCC-25 cells characterized by MYBBP1A
low
pAKT
high 
expression showed 
resistance towards etoposide treatment. These data further underscore the initial assumption that 
loss of MYBBP1A and PI3K activation results in bypassing senescence and resume cancer 
progression in SCC-25 cells. It will be interesting to investigate how stabilization of MYBBP1A 
changes behavior of SCC-25 cells upon treatment with genotoxic stimuli and might sensitize 
these cells towards etoposide or irradiation.  
5.5 Relevance of the senescent phenotype in cancer 
progression and treatment strategies  
There have been many experimentally derived lines of evidence to support the concept that 
senescence may have evolved to initially protect humans against the formation of early onset 
cancers. Moreover a series of studies identified senescence markers in several paraneoplastic 
lesions, both in humans and in mice (110, 111, 113, 114). Furthermore, loss of tumor 
suppressors, such as PTEN, RB1, neurofibromin 1 (NF1) and inositol polyphosphate-4-
phosphatase, typeII (INPP4B) appear to initiate senescence in premalignant tumors (89, 114, 
204, 205). Thus, it is conceivable that, in premalignant cells the engagement of senescence halted 
further progression; the frequency of overtly malignant tumors indicates that many cells either do 
not have fully active senescence programs or develop bypass mechanisms to regain proliferation 
capabilities.   
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Figure 5.2: Schematic model for the inverse regulation of MYBBP1A and PI3K-mTOR-AKT 
signaling pathways in the establishment of senescence and tumor progression. Inverse regulation of 
MYBBP1A and AKT(Ser473) phosphorylation is a characteristic feature of senescent tumor cells. 
Moreover, the presented results suggest a more critical role of the mTOR/AKT pathway for the poor 
clinical outcome of patients with low MYBBP1A levels. A direct link between the induction of 
senescence and radioresistance has been proposed previously and is most likely due to tumor cell survival 
and growth by paracrine action of SASP factors.    
 
Several of the earliest studies looked at the role of two major tumor suppressors, p53 and RB1 
and found that following inactivation, cells were able to bypass senescence after being 
challenged with DNA damage (206, 207). Furthermore, other investigators found that the 
disruption of p21 and p16 expression promotes the reversal of the senescent phenotype (208, 
209). Additional findings suggest that RAS and BRAF mutations acquired by the immortal cells 
may trigger an alternative mechanism contributing to the evasion of senescence (177, 210). The 
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investigators further showed that subsets of tumor cells emerge from a senescent state were more 
resistant to chemotherapeutics than the parental cells (211). This is further complicated by the 
fact that senescent cells still appear to be metabolically active retaining the potential to secrete 
paracrine acting factors. Thus during the course of tumorigenesis, senescence escape can be 
facilitated by the proinflammatory signature of the SASP factors (108). Moreover, increasing 
evidence, particularly from sophisticated mouse models show that in the context of a 
malignancy, senescent cells actively communicate with neighboring cells and the extracellular 
matrix through SASP factors, which can facilitate cellular proliferation and tumorigenesis (108, 
212). For example, secreted pro-inflammatory factors such as VEGF, GRO1, IL-6 and IL-8 
enhance invasion and induce an epithelial to mesenchymal transition in carcinoma cells, a 
phenotype shown to be resistant to chemotherapy and radiation (128, 140, 213, 214). 
Accordingly, xenotransplantation of senescent cells with pre-malignant cells was shown to 
facilitate the proliferation and invasiveness of mouse and human epithelial tumor cells in 
immunocompromised mice (130, 131, 215, 216).  
In solid tumors, the treatment with chemotherapeutics and ionizing radiation has been shown to 
induce the senescent phenotype (217, 218). This has been verified in evaluations of lung, 
prostate and breast carcinoma patients receiving neoadjuvant therapy, which revealed a marked 
increase in the expression of senescence markers in the resected tumors (128, 139, 194). There 
have been an increasing number of reports across several cancer types indicating that senescence 
is associated with a poor therapeutic index to cancer therapeutics. The regimens currently used to 
apply anti-cancer therapeutics represent an ideal scenario for microenvironment damage 
responses-resulting in senescence to promote resistance. This observation appears consistent 
with a previous study using malignant pleural mesothelioma. In this study chemotherapy 
resistance was described in patients whose tumors showed evidence of senescence while a 
substantially higher apoptosis rate was observed in the subset of patients that did not exhibit a 
change in senescence markers (219). Furthermore, an induction of tumor cell senescence 
following neoadjuvant therapy was associated with a poor clinical outcome (219). In line with 
this data, Waldman and coworkers described increased clonogenic growth in the presence of 
irradiation-arrested bystander cells (220). Thus, the adverse consequences of senescence during 
the malignant progression appears to be consistent with the presented results, demonstrating that 
DNA damaging agents induce senescence phenotypes marked by a MYBBP1A
low
pAKT
high
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staining pattern critically contributing to poor clinical outcomes, most likely due to the treatment 
failure and growth by paracrine action of SASP factors. Our current knowledge firmly centered 
on the concept that the presence of senescent cells in malignant tumors may have adverse 
consequences in a clinical setting and careful individualized medical indications need to be 
considered when targeting senescence effectors for cancer therapy.  
In the future new therapeutic strategies to enhance senescent cell clearance in malignant tumors 
should be tested to improve the clinical outcome. Therefore, it is worth speculating that 
interference with MYBBP1A and PI3K/mTOR/AKT pathways will be beneficial for improving 
the clinical outcome of HNSCC patients. Currently, inhibitors specifically targeting 
PI3K/mTOR/AKT pathways are in clinical trials against a variety of different advanced cancers 
(51, 200, 221). However, it is still uncertain which tumors are more likely to respond to this kind 
of targeted therapy. Nevertheless, a follow-up study will be required to determine the impact of 
restoration of MYBBP1A on the potential of reverting senescent cells back to their normal 
functioning state. In light of the present data in which PI3K inhibitor (LY294002) has been 
found to restore MYBBP1A expression by an unknown mechanism, the use of PI3K inhibitors 
are already in the clinical trials for treating HNSCC patients in conjunction with chemotherapy 
or cetuximab (31). The clinical benefit of these drugs might be due to the rescue of pre-/post-
senescent cells from their fate. Accordingly, AKT inhibitors and the mTOR inhibitors 
rapamycin, everolimus and temsirolimus are being assessed for HNSCC at the phase II stage in 
neoadjuvant and recurrent/metastatic settings (31).     
As such, there are a number of other therapeutic avenues of research that have the potential to 
eliminate senescent cells or prevent their accumulation, and reconstitution of effective 
senescence surveillance is one of them. In support of this concept, a recent study found that 
injection of PolyI:C, was able to facilitate the elimination of senescent cells in fibrotic liver 
(119). However, robust stimulation of the immune system in aged individuals should be taken 
with caution, since it might be able to refuel the already existing systemic inflammation. Of note, 
apart from the elimination of senescent cells, drugs which can modulate SASP or the upstream 
regulators such as p38 MAP kinase and NFκB to reduce inflammation could also be beneficial to 
eliminate the adverse activities of senescent cells. For example, inhibiting NFκB signaling was 
resulted in suppression of the SASP phenotype and enhancement of tumor response to 
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chemotherapy in a mouse model of lymphoma (161). Alternative strategies could be the design 
of pharmacological compounds that can specially induce programmed cell death in senescent 
cells or block the road to senescence following neoadjuvant therapy. This will provide an 
effective means for elimination of senescent cells regardless of the reason for their presence. 
However, such a drug is not yet available; still some existing compounds like mTOR inhibitors 
and Sirt6 activators might produce a similar outcome and might be of-high-interest to purse in 
the following years (222, 223). Several reports have suggested that restoring the activity of tumor 
suppressor protein p53 by low-molecular-weight compounds to promote the immune mediated 
clearance and targeted interference of p16
Ink4a
 gene to selectively remove the senescent cells via 
drug induced apoptosis could also be used as an attractive and powerful approach (108, 224, 
225). In addition senescence immunotherapy using senescence associated antigens, which would 
be specific enough to allow efficient recognition of senescent cells could be much more effective 
preventing its deleterious effects. However, it would also be necessary to investigate how each of 
these strategies affects the beneficial role of senescent cells in wound healing or pathological as 
well as physiological conditions. Interestingly, change in life style including avoidance of 
damaging agents like cigarettes and UV-light, caloric restriction and physical exercise were 
reported to affect prevalence of senescent cells in tissues (226). Accordingly, the outcome of 
anticancer therapy is not only determined by the quantitative effect on cancer cells forced to 
irreversibly exit the cell cycle but may also depend on novel capabilities acquired by senescence 
cells. Thus, understanding the circumstances under which these responses are triggered will be 
important for the development of personalized medicine.  
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5.6 Conclusion and Perspectives  
In summary, the present work provides experimental evidence for the existence of a 
MYBBP1A
low
pAKT(Ser473)
high 
phenotype in the onset and maintenance of senescence induced 
by genotoxic stress. In accordance with published reports, our data confirmed intracellular 
translocation and subsequent degradation of MYBBP1A in response to DNA damage. But for the 
first time we demonstrated a causal link between the loss of MYBBP1A and the establishment of 
a senescent phenotype after etoposide treatment. It is worth noting that silencing of MYBBP1A 
was not sufficient to trigger senescence in tumor cell lines, but it modulated the efficacy of 
genotoxic-induced senescence and augmented resistance to irradiation. Interestingly a direct link 
between the induction of senescence and radioresistance has been proposed previously and is 
most likely due to tumor cell survival and growth by paracrine action of SASP factors. Although, 
the precise molecular mechanism by which MYBBP1A regulates DNA damage induced 
senescence remains elusive and warrants further investigation, our study revealed an inverse 
regulation of MYBBP1A and AKT(Ser473) phosphorylation as a characteristic feature of 
senescent tumor cells. Moreover, the presence of MYBBP1A
low
pAKT(Ser473)
high
 staining 
pattern serves as a promising biomarker for OPSCC patients at high-risk for treatment failure. 
Remarkably a significant correlation with progression-free or overall survival was not found 
considering pAKT(Thr308) levels, suggesting a more critical role of the mTOR/AKT pathway 
for the clinical behavior of OPSCCs with low MYBBP1A levels. This data proposes a model 
(Fig. 5.3) in which tumor cells with a MYBBP1A
low
 but pAkt(Ser473)
high
 protein pattern have a 
senescent-like phenotype and might critically contribute to tumor progression due to the 
emergence of highly malignant and/or therapy resistant tumor cells. Indeed, our data 
demonstrated that SCC-25 cells represent a bona fide in vitro model for malignant and invasive 
tumor cells, where loss of MYBBP1A and PI3K/AKT activation results in bypassing senescence 
and resume cancer progression, presumably in the setting of additional stochastic events. 
According to this data, additional markers to define pre-/post-senescence phenotypes would be 
an interesting starting point for further studies.  
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Figure 5.3: Schematic model of the novel MYBBP1A and PI3K/AKT cascade in HNSCC. Left panel: 
Model for attenuation of MYBBP1A and AKT phosphorylation following genotoxic stress promotes 
tumor progression due to a higher resistance to therapy and secretion of SASP factors. Right panel: 
Restoration of MYBBP1A protein or pharmacological inhibition of PI3K/mTOR/AKT pathway is an 
attractive new concept to eliminate the senescent cells, thus sensitize tumor cells for available treatment 
options resulting in better outcome for patients. 
 
Altogether, this new data represents significant progress in our understanding of how the 
presence of senescent cells in malignant tumors are associated with a poor therapeutic index and 
provides a strong rationale for cancer therapeutics that prevents senescence by-pass, as emergent 
cells appear to have highly drug resistant phenotypes. Thus, the restoration of MYBBP1A 
function or the pharmacological inhibition of the PI3K/mTOR/AKT pathway is an attractive new 
concept to sensitize tumor cells for available treatment options, but also to establish new 
strategies for targeted therapy with the potential of elimination of senescent cells. Moreover, the 
obtained data strongly suggests that the abundance of MYBBP1A
low
pAKT(Ser473)
high
 senescent 
                                                                           91                                                                   DISCUSSION                           
  
tumor cells in primary tumors, but also following tumor relapse, could serve as a reliable 
biomarker for treatment decision making and to stratify HNSCC patients at high risk for 
treatment failure. This might also be of clinical relevance for other human malignancies with 
similar etiology and treatment options. However, a better understanding of the underlying 
molecular principles with regard to the regulation and function of MYBBP1A and appropriate 
preclinical model systems resembling the complexity of the tumor tissue architecture are 
urgently needed. Despite the role of MYBBP1A in early embryogenesis, a critical function in 
adult tissue function or homeostasis has not been demonstrated yet. In this regard, the 
identification of MYBBP1A-dependent gene regulatory networks in cellular senescence could 
potentially open up new routes to identify a suitable druggable target other than MYBBP1A 
itself. Thus, potential therapeutic interventions could be combined with new strategies to 
facilitate the elimination of senescent cells as a novel avenue for treatment of malignant cancers 
and health span extension.   
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